{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 12098, "items": [{"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T19:42:41Z", "timestamp": 1574451761077}, "reference-count": 0, "publisher": "Bentham Science Publishers Ltd.", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["MRMC"], "published-print": {"date-parts": [[2010, 9, 1]]}, "DOI": "10.2174/138955710792007196", "type": "journal-article", "created": {"date-parts": [[2010, 7, 31]], "date-time": "2010-07-31T11:46:41Z", "timestamp": 1280576801000}, "page": "887-904", "source": "Crossref", "is-referenced-by-count": 52, "title": ["Targeted Enzyme Prodrug Therapies"], "prefix": "10.2174", "volume": "10", "author": [{"given": "N.", "family": "Schellmann", "sequence": "first", "affiliation": []}, {"given": "P.M.", "family": "Deckert", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Bachran", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Fuchs", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Bachran", "sequence": "additional", "affiliation": []}], "member": "965", "container-title": ["Mini-Reviews in Medicinal Chemistry"], "language": "en", "link": [{"URL": "http://eurekaselect.com/article/download/86645", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2015, 11, 23]], "date-time": "2015-11-23T09:15:09Z", "timestamp": 1448270109000}, "score": 46.80693, "issued": {"date-parts": [[2010, 9, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 9, 1]]}, "issue": "10"}, "alternative-id": ["LiveAll1"], "URL": "http://dx.doi.org/10.2174/138955710792007196", "ISSN": ["1389-5575"], "issn-type": [{"value": "1389-5575", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T17:52:03Z", "timestamp": 1574445123607}, "reference-count": 0, "publisher": "Bentham Science Publishers Ltd.", "issue": "999", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["MRMC"], "published-print": {"date-parts": [[2010, 7, 13]]}, "DOI": "10.2174/1389210205608765575", "type": "journal-article", "created": {"date-parts": [[2010, 7, 14]], "date-time": "2010-07-14T16:37:26Z", "timestamp": 1279125446000}, "page": "1-18", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeted Enzyme Prodrug Therapies"], "prefix": "10.2174", "volume": "999", "author": [{"given": "N.", "family": "Schellmann", "sequence": "first", "affiliation": []}, {"given": "P.M.", "family": "Deckert", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Bachran", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Fuchs", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Bachran", "sequence": "additional", "affiliation": []}], "member": "965", "container-title": ["Mini-Reviews in Medicinal Chemistry"], "language": "en", "deposited": {"date-parts": [[2010, 7, 14]], "date-time": "2010-07-14T16:37:28Z", "timestamp": 1279125448000}, "score": 46.80693, "issued": {"date-parts": [[2010, 7, 13]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 7, 13]]}, "issue": "999"}, "alternative-id": ["LiveAll1"], "URL": "http://dx.doi.org/10.2174/1389210205608765575", "ISSN": ["1389-5575"], "issn-type": [{"value": "1389-5575", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T09:52:08Z", "timestamp": 1574848328389}, "reference-count": 11, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 9, 1]], "date-time": "2017-09-01T00:00:00Z", "timestamp": 1504224000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Advanced Drug Delivery Reviews"], "published-print": {"date-parts": [[2017, 9]]}, "DOI": "10.1016/j.addr.2017.10.006", "type": "journal-article", "created": {"date-parts": [[2017, 10, 18]], "date-time": "2017-10-18T19:17:52Z", "timestamp": 1508354272000}, "page": "1", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 10, "title": ["Enzyme prodrug therapies and therapeutic enzymes"], "prefix": "10.1016", "volume": "118", "author": [{"given": "Brigitte", "family": "St\u00e4dler", "sequence": "first", "affiliation": []}, {"given": "Alexander N.", "family": "Zelikin", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Advanced Drug Delivery Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169409X1730220X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169409X1730220X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 7, 14]], "date-time": "2018-07-14T21:29:40Z", "timestamp": 1531603780000}, "score": 28.863136, "issued": {"date-parts": [[2017, 9]]}, "references-count": 11, "alternative-id": ["S0169409X1730220X"], "URL": "http://dx.doi.org/10.1016/j.addr.2017.10.006", "ISSN": ["0169-409X"], "issn-type": [{"value": "0169-409X", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Enzyme prodrug therapies and therapeutic enzymes", "name": "articletitle", "label": "Article Title"}, {"value": "Advanced Drug Delivery Reviews", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.addr.2017.10.006", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "simple-article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2017 Published by Elsevier B.V.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T21:37:47Z", "timestamp": 1574804267199}, "reference-count": 171, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 9, 1]], "date-time": "2017-09-01T00:00:00Z", "timestamp": 1504224000000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/501100003554", "name": "Lundbeck Foundation", "doi-asserted-by": "publisher", "award": ["R108-2012-10354", "R164-2013-15291"]}, {"DOI": "10.13039/501100002341", "name": "Academy of Finland", "doi-asserted-by": "publisher", "award": ["308329"]}, {"name": "European Research Council Consolidator", "award": ["ERC-2013-CoG 617336 BTVI"]}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Advanced Drug Delivery Reviews"], "published-print": {"date-parts": [[2017, 9]]}, "DOI": "10.1016/j.addr.2017.06.013", "type": "journal-article", "created": {"date-parts": [[2017, 7, 1]], "date-time": "2017-07-01T16:31:19Z", "timestamp": 1498926679000}, "page": "65-77", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 42, "title": ["Prodrugs in medicinal chemistry and enzyme prodrug therapies"], "prefix": "10.1016", "volume": "118", "author": [{"given": "Raoul", "family": "Walther", "sequence": "first", "affiliation": []}, {"given": "Jarkko", "family": "Rautio", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0002-9864-321X", "authenticated-orcid": false, "given": "Alexander N.", "family": "Zelikin", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Advanced Drug Delivery Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169409X17300972?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169409X17300972?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 9, 28]], "date-time": "2019-09-28T04:52:10Z", "timestamp": 1569646330000}, "score": 24.883497, "issued": {"date-parts": [[2017, 9]]}, "references-count": 171, "alternative-id": ["S0169409X17300972"], "URL": "http://dx.doi.org/10.1016/j.addr.2017.06.013", "ISSN": ["0169-409X"], "issn-type": [{"value": "0169-409X", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Prodrugs in medicinal chemistry and enzyme prodrug therapies", "name": "articletitle", "label": "Article Title"}, {"value": "Advanced Drug Delivery Reviews", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.addr.2017.06.013", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2017 Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T19:37:58Z", "timestamp": 1574278678896}, "reference-count": 0, "publisher": "Bentham Science Publishers Ltd.", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CDT"], "published-print": {"date-parts": [[2009, 2, 1]]}, "DOI": "10.2174/138945009787354584", "type": "journal-article", "created": {"date-parts": [[2009, 2, 3]], "date-time": "2009-02-03T23:55:48Z", "timestamp": 1233705348000}, "page": "140-151", "source": "Crossref", "is-referenced-by-count": 45, "title": ["Saponins as Tool for Improved Targeted Tumor Therapies"], "prefix": "10.2174", "volume": "10", "author": [{"given": "H.", "family": "Fuchs", "sequence": "first", "affiliation": []}, {"given": "D.", "family": "Bachran", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Panjideh", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Schellmann", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Weng", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Melzig", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Sutherland", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Bachran", "sequence": "additional", "affiliation": []}], "member": "965", "container-title": ["Current Drug Targets"], "language": "en", "link": [{"URL": "http://eurekaselect.com/article/download/68637", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2015, 11, 23]], "date-time": "2015-11-23T08:24:27Z", "timestamp": 1448267067000}, "score": 24.399052, "issued": {"date-parts": [[2009, 2, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 2, 1]]}, "issue": "2"}, "alternative-id": ["LiveAll1"], "URL": "http://dx.doi.org/10.2174/138945009787354584", "ISSN": ["1389-4501"], "issn-type": [{"value": "1389-4501", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:56:28Z", "timestamp": 1574283388170}, "reference-count": 0, "publisher": "Japan Institute of Heterocyclic Chemistry", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["HETEROCYCLES"], "published-print": {"date-parts": [[1993]]}, "DOI": "10.3987/com-92-s22", "type": "journal-article", "created": {"date-parts": [[2009, 3, 4]], "date-time": "2009-03-04T05:09:33Z", "timestamp": 1236143373000}, "page": "339", "source": "Crossref", "is-referenced-by-count": 25, "title": ["Synthesis of a Cephalosporin-Doxorubicin Antitumor Prodrug: A Substrate for an Antibody-targeted Enzyme"], "prefix": "10.3987", "volume": "35", "author": [{"given": "Louis", "family": "N. Jungheim", "sequence": "first", "affiliation": []}, {"given": "Timothy", "family": "A. Shepherd", "sequence": "additional", "affiliation": []}, {"given": "James", "family": "K. Kling", "sequence": "additional", "affiliation": []}], "member": "2364", "container-title": ["HETEROCYCLES"], "language": "en", "deposited": {"date-parts": [[2011, 8, 16]], "date-time": "2011-08-16T22:00:17Z", "timestamp": 1313532017000}, "score": 24.238659, "issued": {"date-parts": [[1993]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993]]}, "issue": "1"}, "alternative-id": ["COM-92-S22"], "URL": "http://dx.doi.org/10.3987/com-92-s22", "ISSN": ["0385-5414"], "issn-type": [{"value": "0385-5414", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T23:20:07Z", "timestamp": 1574464807956}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 4, 1]], "date-time": "2012-04-01T00:00:00Z", "timestamp": 1333238400000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "https://www.elsevier.com/open-access/userlicense/1.0/", "start": {"date-parts": [[2014, 2, 17]], "date-time": "2014-02-17T00:00:00Z", "timestamp": 1392595200000}, "delay-in-days": 687, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Osteoarthritis and Cartilage"], "published-print": {"date-parts": [[2012, 4]]}, "DOI": "10.1016/j.joca.2012.02.613", "type": "journal-article", "created": {"date-parts": [[2012, 3, 30]], "date-time": "2012-03-30T06:51:05Z", "timestamp": 1333090265000}, "page": "S3", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Novel and targeted therapies for OA"], "prefix": "10.1016", "volume": "20", "author": [{"given": "N.", "family": "Lane", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Osteoarthritis and Cartilage"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1063458412006851?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1063458412006851?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 24]], "date-time": "2018-11-24T19:29:11Z", "timestamp": 1543087751000}, "score": 21.70493, "issued": {"date-parts": [[2012, 4]]}, "references-count": 0, "alternative-id": ["S1063458412006851"], "URL": "http://dx.doi.org/10.1016/j.joca.2012.02.613", "ISSN": ["1063-4584"], "issn-type": [{"value": "1063-4584", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T00:19:20Z", "timestamp": 1574122760287}, "reference-count": 1, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nuclear Medicine Communications"], "published-print": {"date-parts": [[2002, 4]]}, "DOI": "10.1097/00006231-200204000-00097", "type": "journal-article", "created": {"date-parts": [[2003, 4, 24]], "date-time": "2003-04-24T14:19:15Z", "timestamp": 1051193955000}, "page": "410", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P17. Radiolabelling of a half mustard prodrug for antibody-directed enzyme prodrug therapy"], "prefix": "10.1097", "volume": "23", "author": [{"given": "N.", "family": "Malik", "sequence": "first", "affiliation": []}, {"given": "S. K.", "family": "Luthra", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Price", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Brady", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Nuclear Medicine Communications"], "language": "en", "deposited": {"date-parts": [[2018, 2, 9]], "date-time": "2018-02-09T00:01:47Z", "timestamp": 1518134507000}, "score": 21.494902, "subtitle": [""], "issued": {"date-parts": [[2002, 4]]}, "references-count": 1, "journal-issue": {"issue": "4"}, "URL": "http://dx.doi.org/10.1097/00006231-200204000-00097", "ISSN": ["0143-3636"], "issn-type": [{"value": "0143-3636", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T14:05:23Z", "timestamp": 1574690723616}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 10]]}, "DOI": "10.1158/1557-3125.advbc-b063", "type": "proceedings-article", "created": {"date-parts": [[2015, 5, 4]], "date-time": "2015-05-04T17:13:52Z", "timestamp": 1430759632000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract B063: Tumor targeting and diagnostic applications of glycosylated nanotubes"], "prefix": "10.1158", "author": [{"given": "Ravi N.", "family": "Singh", "sequence": "first", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 7, 31]]}, "event": {"name": "Abstracts: AACR Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications - October 3-6, 2013; San Diego, CA"}, "container-title": ["Targeted Therapies"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1557-3125.ADVBC-B063", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T17:47:56Z", "timestamp": 1557424076000}, "score": 21.268303, "issued": {"date-parts": [[2013, 10]]}, "references-count": 0, "alternative-id": ["10.1158/1557-3125.ADVBC-B063"], "URL": "http://dx.doi.org/10.1158/1557-3125.advbc-b063"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T13:19:13Z", "timestamp": 1574515153509}, "reference-count": 48, "publisher": "Public Library of Science (PLoS)", "issue": "11", "license": [{"URL": "http://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2012, 11, 13]], "date-time": "2012-11-13T00:00:00Z", "timestamp": 1352764800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["www.plosone.org"], "crossmark-restriction": false}, "short-container-title": ["PLoS ONE"], "DOI": "10.1371/journal.pone.0049619", "type": "journal-article", "created": {"date-parts": [[2012, 11, 13]], "date-time": "2012-11-13T22:01:31Z", "timestamp": 1352844091000}, "page": "e49619", "update-policy": "http://dx.doi.org/10.1371/journal.pone.corrections_policy", "source": "Crossref", "is-referenced-by-count": 19, "title": ["Substrate Mediated Enzyme Prodrug Therapy"], "prefix": "10.1371", "volume": "7", "author": [{"given": "Betina", "family": "Fejerskov", "sequence": "first", "affiliation": []}, {"given": "Alexander N.", "family": "Zelikin", "sequence": "additional", "affiliation": []}], "member": "340", "published-online": {"date-parts": [[2012, 11, 13]]}, "reference": [{"key": "ref1", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1039/B916705F", "article-title": "Synthetic hydrogels for controlled stem cell differentiation", "volume": "6", "author": "SQ Liu", "year": "2010", "journal-title": "Soft Matter"}, {"key": "ref2", "doi-asserted-by": "crossref", "first-page": "1124", "DOI": "10.1126/science.1214804", "article-title": "Designing Cell-Compatible Hydrogels for Biomedical Applications", "volume": "336", "author": "D Seliktar", "year": "2012", "journal-title": "Science"}, {"key": "ref3", "doi-asserted-by": "crossref", "first-page": "631", "DOI": "10.1007/s11095-008-9801-2", "article-title": "PEG Hydrogels for the Controlled Release of Biomolecules in Regenerative Medicine", "volume": "26", "author": "CC Lin", "year": "2009", "journal-title": "Pharm Res"}, {"key": "ref4", "doi-asserted-by": "crossref", "first-page": "1379", "DOI": "10.1016/j.addr.2006.09.004", "article-title": "Hydrogels in controlled release formulations: Network design and mathematical modeling", "volume": "58", "author": "C-C Lin", "year": "2006", "journal-title": "Adv Drug Deliv Rev"}, {"key": "ref5", "doi-asserted-by": "crossref", "first-page": "3307", "DOI": "10.1002/adma.200802106", "article-title": "Hydrogels in Regenerative Medicine", "volume": "21", "author": "BV Slaughter", "year": "2009", "journal-title": "Adv Mater"}, {"key": "ref6", "doi-asserted-by": "crossref", "first-page": "2193", "DOI": "10.1039/C1CS15203C", "article-title": "Injectable and biodegradable hydrogels: gelation, biodegradation and biomedical applications", "volume": "41", "author": "Y Li", "year": "2012", "journal-title": "Chem Soc Rev"}, {"key": "ref7", "doi-asserted-by": "crossref", "first-page": "1993", "DOI": "10.1016/j.polymer.2008.01.027", "article-title": "Hydrogels in drug delivery: Progress and challenges", "volume": "49", "author": "TR Hoare", "year": "2008", "journal-title": "Polymer"}, {"key": "ref8", "doi-asserted-by": "crossref", "first-page": "5087", "DOI": "10.1016/j.biomaterials.2007.07.021", "article-title": "Microengineered hydrogels for tissue engineering", "volume": "28", "author": "A Khademhosseini", "year": "2007", "journal-title": "Biomaterials"}, {"key": "ref9", "doi-asserted-by": "crossref", "first-page": "144", "DOI": "10.1016/S0006-3495(00)76279-5", "article-title": "Cell movement is guided by the rigidity of the substrate", "volume": "79", "author": "CM Lo", "year": "2000", "journal-title": "Biophys J"}, {"key": "ref10", "doi-asserted-by": "crossref", "first-page": "299", "DOI": "10.1039/B610522J", "article-title": "Soft biological materials and their impact on cell function", "volume": "3", "author": "I Levental", "year": "2007", "journal-title": "Soft Matter"}, {"key": "ref11", "doi-asserted-by": "crossref", "first-page": "3181", "DOI": "10.1021/cr940351u", "article-title": "Polymeric Systems for Controlled Drug Release", "volume": "99", "author": "KE Uhrich", "year": "1999", "journal-title": "Chem Rev"}, {"key": "ref12", "doi-asserted-by": "crossref", "first-page": "321", "DOI": "10.1002/mabi.201000206", "article-title": "Affinity-Based Drug Delivery", "volume": "11", "author": "NX Wang", "year": "2011", "journal-title": "Macromol Biosci"}, {"key": "ref13", "unstructured": "Hosta-Rigau L, Jensen BEB, Fjesdso KS, Postma A, Li GX, <etal>et al</etal>.. (2012) Surface-Adhered Composite Poly(Vinyl Alcohol) Physical Hydrogels: Polymersome-Aided Delivery of Therapeutic Molecules. Adv Healthcare Mater 10.1002/adhm.201200092.", "DOI": "10.1002/adhm.201200092", "doi-asserted-by": "crossref"}, {"key": "ref14", "doi-asserted-by": "crossref", "first-page": "1071", "DOI": "10.1080/02713680500346633", "article-title": "Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery", "volume": "30", "author": "D Gulsen", "year": "2005", "journal-title": "Current Eye Research"}, {"key": "ref15", "doi-asserted-by": "crossref", "first-page": "177", "DOI": "10.1038/nrd744", "article-title": "Building drug delivery into tissue engineering", "volume": "1", "author": "WM Saltzman", "year": "2002", "journal-title": "Nature Rev Drug Discov"}, {"key": "ref16", "doi-asserted-by": "crossref", "first-page": "1175", "DOI": "10.1517/17425247.2011.588698", "article-title": "Drug delivery in soft tissue engineering", "volume": "8", "author": "K Ladewig", "year": "2011", "journal-title": "Exp Opin Drug Deliv"}, {"key": "ref17", "doi-asserted-by": "crossref", "first-page": "445", "DOI": "10.1016/j.tibtech.2003.08.002", "article-title": "Polymeric cryogels as promising materials of biotechnological interest", "volume": "21", "author": "VI Lozinsky", "year": "2003", "journal-title": "Trends Biotechnol"}, {"key": "ref18", "doi-asserted-by": "crossref", "first-page": "182", "DOI": "10.1016/S0141-0229(96)00110-X", "article-title": "Poly(vinyl alcohol) cryogels employed as matrices for cell immobilization.2. Entrapped cells resemble porous fillers in their effects on the properties of PVA-cryogel carrier", "volume": "20", "author": "VI Lozinsky", "year": "1997", "journal-title": "Enzyme Microb Technol"}, {"key": "ref19", "doi-asserted-by": "crossref", "first-page": "4623", "DOI": "10.1073/pnas.0807506106", "article-title": "Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold", "volume": "106", "author": "S Koutsopoulos", "year": "2009", "journal-title": "Proc Nat Acad Sci USA"}, {"key": "ref20", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.1002/bit.22911", "article-title": "Characterization of Protein Release From Hydrolytically Degradable Poly(Ethylene Glycol) Hydrogels", "volume": "108", "author": "SP Zustiak", "year": "2011", "journal-title": "Biotechnol Bioeng"}, {"key": "ref21", "doi-asserted-by": "crossref", "first-page": "797", "DOI": "10.1021/mz3000896", "article-title": "Layer-by-Layer Enzymatic Platform for Stretched-Induced Reactive Release", "volume": "1", "author": "C Vogt", "year": "2012", "journal-title": "ACS Macro Letters"}, {"key": "ref22", "doi-asserted-by": "crossref", "first-page": "731", "DOI": "10.1038/nmat2504", "article-title": "Mechanotransductive surfaces for reversible biocatalysis activation", "volume": "8", "author": "D Mertz", "year": "2009", "journal-title": "Nat Mater"}, {"key": "ref23", "doi-asserted-by": "crossref", "first-page": "4625", "DOI": "10.1039/c2sm07075h", "article-title": "Surface adhered poly(vinyl alcohol) physical hydrogels as tools for rational design of intelligent biointerfaces", "volume": "8", "author": "BEB Jensen", "year": "2012", "journal-title": "Soft Matter"}, {"key": "ref24", "doi-asserted-by": "crossref", "first-page": "10216", "DOI": "10.1021/la201595e", "article-title": "Poly(vinyl alcohol) Physical Hydrogels: Noncryogenic Stabilization Allows Nano- and Microscale Materials Design", "volume": "27", "author": "BEB Jensen", "year": "2011", "journal-title": "Langmuir"}, {"key": "ref25", "doi-asserted-by": "crossref", "first-page": "85", "DOI": "10.1039/C1PY00429H", "article-title": "Macromolecular design of poly(vinyl alcohol) by RAFT polymerization", "volume": "3", "author": "AAA Smith", "year": "2012", "journal-title": "Polymer Chemistry"}, {"key": "ref26", "doi-asserted-by": "crossref", "first-page": "37", "DOI": "10.1007/3-540-46414-X_2", "article-title": "Structure and applications of poly(vinyl alcohol) hydrogels produced by conventional crosslinking or by freezing/thawing methods", "volume": "153", "author": "CM Hassan", "year": "2000", "journal-title": "Adv Polym Sci"}, {"key": "ref27", "doi-asserted-by": "crossref", "first-page": "1293", "DOI": "10.1002/mabi.201100145", "article-title": "Poly(Vinyl Alcohol) Physical Hydrogels: New Vista on a Long Serving Biomaterial", "volume": "11", "author": "MH Alves", "year": "2011", "journal-title": "Macromol Biosci"}, {"key": "ref28", "doi-asserted-by": "crossref", "first-page": "331", "DOI": "10.1016/j.jss.2010.03.070", "article-title": "Porous Poly(vinyl alcohol)-Alginate Gel Hybrid Construct for Neocartilage Formation Using Human Nasoseptal Cells", "volume": "163", "author": "DA Bichara", "year": "2010", "journal-title": "J Surg Res"}, {"key": "ref29", "doi-asserted-by": "crossref", "first-page": "1883", "DOI": "10.1096/fasebj.13.14.1883", "article-title": "Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells", "volume": "13", "author": "SN Bhatia", "year": "1999", "journal-title": "FASEB Journal"}, {"key": "ref30", "doi-asserted-by": "crossref", "first-page": "120", "DOI": "10.1038/nbt1361", "article-title": "Microscale culture of human liver cells for drug development", "volume": "26", "author": "SR Khetani", "year": "2008", "journal-title": "Nat Biotech"}, {"key": "ref31", "doi-asserted-by": "crossref", "first-page": "751", "DOI": "10.1089/ten.2006.12.751", "article-title": "Hepatocyte and Kupffer cells co-cultured on micropatterned surfaces to optimize hepatocyte function", "volume": "12", "author": "YS Zinchenko", "year": "2006", "journal-title": "Tissue Engineering"}, {"key": "ref32", "doi-asserted-by": "crossref", "first-page": "2494", "DOI": "10.1021/nn100634r", "article-title": "Drug Releasing Polymer Thin Films: New Era of Surface-Mediated Drug Delivery", "volume": "4", "author": "AN Zelikin", "year": "2010", "journal-title": "ACS Nano"}, {"key": "ref33", "doi-asserted-by": "crossref", "first-page": "4981", "DOI": "10.1021/am3013467", "article-title": "Engineering Surface Adhered Poly(vinyl alcohol) Physical Hydrogels as Enzymatic Microreactors", "volume": "4", "author": "B Fejerskov", "year": "2012", "journal-title": "ACS Appl Mater Interfaces"}, {"key": "ref34", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1111/j.1747-0285.2009.00856.x", "article-title": "Antibody-Directed Enzyme Prodrug Therapy: A Promising Approach for a Selective Treatment of Cancer Based on Prodrugs and Monoclonal Antibodies", "volume": "74", "author": "LF Tietze", "year": "2009", "journal-title": "Chem Biol Drug Design"}, {"key": "ref35", "doi-asserted-by": "crossref", "first-page": "151", "DOI": "10.1016/S0169-409X(97)00032-X", "article-title": "Antibody-directed enzyme prodrug therapy (ADEPT): A review", "volume": "26", "author": "I NiculescuDuvaz", "year": "1997", "journal-title": "Adv Drug Deliv Rev"}, {"key": "ref36", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1002/cmdc.200700159", "article-title": "Prodrug Strategies in Anticancer Chemotherapy", "volume": "3", "author": "F Kratz", "year": "2008", "journal-title": "ChemMedChem"}, {"key": "ref37", "doi-asserted-by": "crossref", "first-page": "187", "DOI": "10.1038/sj.cgt.7700999", "article-title": "Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes", "volume": "14", "author": "KC Chen", "year": "2007", "journal-title": "Cancer Gene Therapy"}, {"key": "ref38", "first-page": "2151", "article-title": "Tumor-Selective Prodrug Activation by Fusion Protein-Mediated Catalysis", "volume": "54", "author": "K Bosslet", "year": "1994", "journal-title": "Cancer Res"}, {"key": "ref39", "first-page": "184", "article-title": "Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy", "volume": "92", "author": "HJ Haisma", "year": "1998", "journal-title": "Blood"}, {"key": "ref40", "doi-asserted-by": "crossref", "first-page": "4013", "DOI": "10.1021/jm970066d", "article-title": "Intensely cytotoxic anthracycline prodrugs: Glucuronides", "volume": "40", "author": "E Bakina", "year": "1997", "journal-title": "J Med Chem"}, {"key": "ref41", "doi-asserted-by": "crossref", "first-page": "1479", "DOI": "10.1016/j.biomaterials.2005.09.015", "article-title": "Micropatterned cell co-cultures using layer-by-layer deposition of extracellular matrix components", "volume": "27", "author": "J Fukuda", "year": "2006", "journal-title": "Biomaterials"}, {"key": "ref42", "doi-asserted-by": "crossref", "first-page": "1303", "DOI": "10.1023/A:1010569322537", "article-title": "New and effective entrapment of polyelectrolyte-enzyme-complexes in LentiKats", "volume": "23", "author": "G Czichocki", "year": "2001", "journal-title": "Biotechnol Letters"}, {"key": "ref43", "doi-asserted-by": "crossref", "first-page": "1969", "DOI": "10.1021/ol015920g", "article-title": "Asymmetric synthesis of an (R)-cyanohydrin using enzymes entrapped in lens-shaped gels", "volume": "3", "author": "H Groger", "year": "2001", "journal-title": "Org Lett"}, {"key": "ref44", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1016/S0378-4347(01)00313-9", "article-title": "Fluorogenic assay for beta-glucuronidase using microchip-based capillary electrophoresis", "volume": "762", "author": "DE Starkey", "year": "2001", "journal-title": "J Chromatography B"}, {"key": "ref45", "unstructured": "Dean RT (1974) Rabbit Beta-Glucuronidase - Purification and Properties, and Existence of Multiple Forms. Biochem J 138: 395-&amp;.", "DOI": "10.1042/bj1380395", "doi-asserted-by": "crossref"}, {"key": "ref46", "doi-asserted-by": "crossref", "first-page": "1391", "DOI": "10.2174/1381612023394485", "article-title": "Beta-glucuronidase-mediated drug release", "volume": "8", "author": "M de Graaf", "year": "2002", "journal-title": "Curr Pharmac Design"}, {"key": "ref47", "doi-asserted-by": "crossref", "first-page": "1340", "DOI": "10.1016/j.addr.2007.08.012", "article-title": "Spatiotemporal control over growth factor signaling for therapeutic neovascularization", "volume": "59", "author": "L Cao", "year": "2007", "journal-title": "Adv Drug Deliv Rev"}, {"key": "ref48", "doi-asserted-by": "crossref", "first-page": "253", "DOI": "10.1002/bit.10569", "article-title": "Formation of steady-state oxygen gradients in vitro - Application to liver zonation", "volume": "82", "author": "JW Allen", "year": "2003", "journal-title": "Biotechnol Bioeng"}], "container-title": ["PLoS ONE"], "language": "en", "link": [{"URL": "http://dx.plos.org/10.1371/journal.pone.0049619", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 5]], "date-time": "2019-07-05T16:15:25Z", "timestamp": 1562343325000}, "score": 21.126444, "editor": [{"given": "Vipul", "family": "Bansal", "sequence": "first", "affiliation": []}], "issued": {"date-parts": [[2012, 11, 13]]}, "references-count": 48, "journal-issue": {"published-online": {"date-parts": [[2012, 11, 13]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1371/journal.pone.0049619", "relation": {"cites": []}, "ISSN": ["1932-6203"], "issn-type": [{"value": "1932-6203", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T01:06:41Z", "timestamp": 1574471201416}, "publisher-location": "Berlin, Heidelberg", "reference-count": 108, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783642275968", "type": "print"}, {"value": "9783642275975", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012]]}, "DOI": "10.1007/978-3-642-27597-5_20", "type": "book-chapter", "created": {"date-parts": [[2012, 4, 23]], "date-time": "2012-04-23T14:07:27Z", "timestamp": 1335190047000}, "page": "261-275", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeted Therapies and Vaccination"], "prefix": "10.1007", "author": [{"given": "Guru", "family": "Sonpavde", "sequence": "first", "affiliation": []}, {"given": "Cora N.", "family": "Sternberg", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 3, 12]]}, "reference": [{"key": "20_CR2_20", "unstructured": "Agus DB, Stadler WM, Shevrin DH et al (2011) Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. J Clin Oncol 29:(suppl; abstr 4531)", "DOI": "10.1200/jco.2011.29.15_suppl.4531", "doi-asserted-by": "crossref"}, {"key": "20_CR3_20", "doi-asserted-by": "publisher", "first-page": "878", "DOI": "10.1158/1078-0432.CCR-05-2013", "volume": "12", "author": "SJ Antonia", "year": "2006", "unstructured": "Antonia SJ, Mirza N, Fricke I et al (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12:878\u2013887: an official journal of the American Association for Cancer Research", "journal-title": "Clin Cancer Res"}, {"key": "20_CR4_20", "doi-asserted-by": "publisher", "first-page": "1050", "DOI": "10.1038/nm1622", "volume": "13", "author": "L Apetoh", "year": "2007", "unstructured": "Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050\u20131059", "journal-title": "Nat Med"}, {"key": "20_CR5_20", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.1053/j.seminoncol.2005.09.006", "volume": "32", "author": "PM Arlen", "year": "2005", "unstructured": "Arlen PM, Kaufman HL, DiPaola RS (2005) Pox viral vaccine approaches. Semin Oncol 32:549\u2013555", "journal-title": "Semin Oncol"}, {"key": "20_CR6_20", "doi-asserted-by": "publisher", "first-page": "2181", "DOI": "10.1016/j.juro.2008.01.099", "volume": "179", "author": "PM Arlen", "year": "2008", "unstructured": "Arlen PM, Bianco F, Dahut WL et al (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181\u20132185; discussion 5\u20136", "journal-title": "J Urol"}, {"key": "20_CR7_20", "unstructured": "Armstrong AJ, Haggman M, Stadler WM et al (2011) Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): safety and efficacy analysis including subgroups. J Clin Oncol 29:(suppl 7; abstr 126)", "DOI": "10.1200/jco.2011.29.7_suppl.126", "doi-asserted-by": "crossref"}, {"key": "20_CR9_20", "doi-asserted-by": "publisher", "first-page": "4563", "DOI": "10.1200/JCO.2007.15.9749", "volume": "26", "author": "G Attard", "year": "2008", "unstructured": "Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563\u20134571", "journal-title": "J Clin Oncol"}, {"key": "20_CR10_20", "doi-asserted-by": "publisher", "first-page": "2912", "DOI": "10.1158/0008-5472.CAN-08-3667", "volume": "69", "author": "G Attard", "year": "2009", "unstructured": "Attard G, Swennenhuis JF, Olmos D et al (2009a) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:2912\u20132918", "journal-title": "Cancer Res"}, {"key": "20_CR11_20", "doi-asserted-by": "publisher", "first-page": "3742", "DOI": "10.1200/JCO.2008.20.0642", "volume": "27", "author": "G Attard", "year": "2009", "unstructured": "Attard G, Reid AH, A\u2019Hern R et al (2009b) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742\u20133748", "journal-title": "J Clin Oncol"}, {"key": "20_CR12_20", "doi-asserted-by": "publisher", "first-page": "458", "DOI": "10.1016/j.ccr.2009.11.006", "volume": "16", "author": "G Attard", "year": "2009", "unstructured": "Attard G, Cooper CS, de Bono JS (2009c) Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16:458\u2013462", "journal-title": "Cancer Cell"}, {"key": "20_CR13_20", "doi-asserted-by": "publisher", "first-page": "4937", "DOI": "10.1158/0008-5472.CAN-08-4531", "volume": "69", "author": "G Attard", "year": "2009", "unstructured": "Attard G, Reid AH, Olmos D, de Bono JS (2009d) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937\u20134940", "journal-title": "Cancer Res"}, {"key": "20_CR14_20", "doi-asserted-by": "publisher", "first-page": "523", "DOI": "10.1111/j.1365-2249.2007.03521.x", "volume": "150", "author": "S Audia", "year": "2007", "unstructured": "Audia S, Nicolas A, Cathelin D et al (2007) Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 150:523\u2013530", "journal-title": "Clin Exp Immunol"}, {"key": "20_CR15_20", "doi-asserted-by": "publisher", "first-page": "667", "DOI": "10.1016/S0093-7754(03)00358-0", "volume": "30", "author": "NH Bander", "year": "2003", "unstructured": "Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ (2003) Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 30:667\u2013676", "journal-title": "Semin Oncol"}, {"key": "20_CR16_20", "doi-asserted-by": "publisher", "first-page": "639", "DOI": "10.1097/CJI.0b013e3181dda23e", "volume": "33", "author": "JT Becker", "year": "2010", "unstructured": "Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG (2010) DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 33:639\u2013647", "journal-title": "J Immunother"}, {"key": "20_CR17_20", "unstructured": "Beer TM, Logothetis C, Sharma P, Gerritsen WR, Ezzeddine R, Fairchild JP, Gagnier P, Chin KM, Cuillerot J (2011) Randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-na\u00efve castration resistant prostate cancer. J Clin Oncol 29: (abstr TPS182) (ClinicalTrials.gov: NCT01057810)", "DOI": "10.1200/jco.2011.29.15_suppl.tps182", "doi-asserted-by": "crossref"}, {"key": "20_CR18_20", "doi-asserted-by": "publisher", "first-page": "242", "DOI": "10.1200/JCO.2007.12.4008", "volume": "26", "author": "DR Berthold", "year": "2008", "unstructured": "Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242\u2013245", "journal-title": "J Clin Oncol"}, {"key": "20_CR19_20", "doi-asserted-by": "publisher", "first-page": "5450", "DOI": "10.1016/j.vaccine.2009.07.005", "volume": "27", "author": "SR Best", "year": "2009", "unstructured": "Best SR, Peng S, Juang CM et al (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27:5450\u20135459", "journal-title": "Vaccine"}, {"key": "20_CR20_20", "doi-asserted-by": "publisher", "first-page": "593", "DOI": "10.1038/ni1201", "volume": "6", "author": "RJ Binder", "year": "2005", "unstructured": "Binder RJ, Srivastava PK (2005) Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 6:593\u2013599", "journal-title": "Nat Immunol"}, {"key": "20_CR21_20", "doi-asserted-by": "publisher", "first-page": "3167", "DOI": "10.1200/JCO.2009.26.7609", "volume": "28", "author": "JR Brahmer", "year": "2010", "unstructured": "Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167\u20133175", "journal-title": "J Clin Oncol"}, {"key": "20_CR22_20", "doi-asserted-by": "crossref", "first-page": "6338", "DOI": "10.4049/jimmunol.170.12.6338", "volume": "170", "author": "M Chakraborty", "year": "2003", "unstructured": "Chakraborty M, Abrams SI, Camphausen K et al (2003) Irradiation of tumor cells up-regulates fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170:6338\u20136347", "journal-title": "J Immunol"}, {"key": "20_CR23_20", "doi-asserted-by": "publisher", "first-page": "4328", "DOI": "10.1158/0008-5472.CAN-04-0073", "volume": "64", "author": "M Chakraborty", "year": "2004", "unstructured": "Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64:4328\u20134337", "journal-title": "Cancer Res"}, {"key": "20_CR24_20", "doi-asserted-by": "publisher", "first-page": "981", "DOI": "10.1016/S1470-2045(09)70229-3", "volume": "10", "author": "Y Chen", "year": "2009", "unstructured": "Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981\u2013991", "journal-title": "Lancet Oncol"}, {"key": "20_CR25_20", "doi-asserted-by": "publisher", "first-page": "10946", "DOI": "10.1158/0008-5472.CAN-05-2018", "volume": "65", "author": "AT Collins", "year": "2005", "unstructured": "Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946\u201310951", "journal-title": "Cancer Res"}, {"key": "20_CR27_20", "doi-asserted-by": "publisher", "first-page": "1496", "DOI": "10.1200/JCO.2009.25.9259", "volume": "28", "author": "DC Danila", "year": "2010", "unstructured": "Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus pre\u00addnisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496\u20131501", "journal-title": "J Clin Oncol"}, {"key": "20_CR28_20", "doi-asserted-by": "publisher", "first-page": "6302", "DOI": "10.1158/1078-0432.CCR-08-0872", "volume": "14", "author": "JS Bono de", "year": "2008", "unstructured": "de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302\u20136309", "journal-title": "Clin Cancer Res"}, {"key": "20_CR29_20", "doi-asserted-by": "publisher", "first-page": "1147", "DOI": "10.1016/S0140-6736(10)61389-X", "volume": "376", "author": "JS Bono de", "year": "2010", "unstructured": "de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154", "journal-title": "Lancet"}, {"key": "20_CR30_20", "doi-asserted-by": "publisher", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "volume": "364", "author": "JS Bono de", "year": "2011", "unstructured": "de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005", "journal-title": "N Engl J Med"}, {"key": "20_CR31_20", "doi-asserted-by": "publisher", "first-page": "5469", "DOI": "10.1158/0008-5472.CAN-08-0594", "volume": "68", "author": "SM Dehm", "year": "2008", "unstructured": "Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469\u20135477", "journal-title": "Cancer Res"}, {"key": "20_CR32_20", "doi-asserted-by": "publisher", "first-page": "580", "DOI": "10.1038/nri2817", "volume": "10", "author": "CG Drake", "year": "2010", "unstructured": "Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580\u2013593", "journal-title": "Nat Rev Immunol"}, {"key": "20_CR33_20", "unstructured": "Drake CG, Scher HI, Gerritsen WR, Ezzeddine R, Fitzmaurice TF, Cuillerot J, Chin KM, Gagnier P (2011) A randomized, double-blind, phase 3 trial comparing ipilimumab vs. placebo following radiotherapy in subjects with castration resistant prostate cancer that have received prior treatment with docetaxel. J Clin Oncol 29: abstract TPS181 (ClinicalTrials.gov: NCT00861614)", "DOI": "10.1200/jco.2011.29.15_suppl.tps181", "doi-asserted-by": "crossref"}, {"key": "20_CR34_20", "doi-asserted-by": "publisher", "first-page": "552", "DOI": "10.1038/sj.bjc.6601127", "volume": "89", "author": "J Edwards", "year": "2003", "unstructured": "Edwards J, Krishna NS, Grigor KM, Bartlett JM (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552\u2013556", "journal-title": "Br J Cancer"}, {"key": "20_CR35_20", "doi-asserted-by": "publisher", "first-page": "228", "DOI": "10.1016/j.ejca.2008.10.026", "volume": "45", "author": "EA Eisenhauer", "year": "2009", "unstructured": "Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247", "journal-title": "Eur J Cancer"}, {"key": "20_CR36_20", "first-page": "2587", "volume": "9", "author": "K Fizazi", "year": "2003", "unstructured": "Fizazi K, Yang J, Peleg S et al (2003) Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587\u20132597", "journal-title": "Clin Cancer Res"}, {"key": "20_CR37_20", "doi-asserted-by": "publisher", "first-page": "813", "DOI": "10.1016/S0140-6736(10)62344-6", "volume": "377", "author": "K Fizazi", "year": "2011", "unstructured": "Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822", "journal-title": "Lancet"}, {"key": "20_CR38_20", "doi-asserted-by": "publisher", "first-page": "2147", "DOI": "10.1200/JCO.2007.15.0532", "volume": "26", "author": "MD Galsky", "year": "2008", "unstructured": "Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26:2147\u20132154: official journal of the American Society of Clinical Oncology", "journal-title": "J Clin Oncol"}, {"key": "20_CR39_20", "doi-asserted-by": "publisher", "first-page": "965", "DOI": "10.1093/annonc/mdp199", "volume": "20", "author": "MD Galsky", "year": "2009", "unstructured": "Galsky MD, Simon K, Sonpavde G et al (2009) Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol 20:965\u2013966: official journal of the European Society for Medical Oncology/ESMO", "journal-title": "Ann Oncol"}, {"key": "20_CR40_20", "doi-asserted-by": "publisher", "first-page": "7985", "DOI": "10.1158/0008-5472.CAN-04-1525", "volume": "64", "author": "CT Garnett", "year": "2004", "unstructured": "Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64:7985\u20137994", "journal-title": "Cancer Res"}, {"key": "20_CR41_20", "author": "W Gerritsen", "year": "2007", "unstructured": "Gerritsen W, Van Den Eertwegh AJ, De Gruijl TD et al (2007) A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (MHRPC). Prostate Cancer Symposium, Orlando (Abstract)", "volume-title": "A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (MHRPC)"}, {"key": "20_CR42_20", "first-page": "2892", "volume": "61", "author": "CW Gregory", "year": "2001", "unstructured": "Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001a) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892\u20132898", "journal-title": "Cancer Res"}, {"key": "20_CR43_20", "first-page": "4315", "volume": "61", "author": "CW Gregory", "year": "2001", "unstructured": "Gregory CW, He B, Johnson RT et al (2001b) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315\u20134319", "journal-title": "Cancer Res"}, {"key": "20_CR44_20", "doi-asserted-by": "publisher", "first-page": "1232", "DOI": "10.1200/JCO.2003.06.100", "volume": "21", "author": "S Halabi", "year": "2003", "unstructured": "Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232\u20131237: official journal of the American Society of Clinical Oncology", "journal-title": "J Clin Oncol"}, {"key": "20_CR45_20", "doi-asserted-by": "publisher", "first-page": "130", "DOI": "10.1038/nm1183", "volume": "11", "author": "BA Hanks", "year": "2005", "unstructured": "Hanks BA, Jiang J, Singh RA et al (2005) Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 11:130\u2013137", "journal-title": "Nat Med"}, {"key": "20_CR46_20", "doi-asserted-by": "publisher", "first-page": "3329", "DOI": "10.1128/JVI.76.7.3329-3337.2002", "volume": "76", "author": "LE Harrington", "year": "2002", "unstructured": "Harrington LE, Most Rv R, Whitton JL, Ahmed R (2002) Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76:3329\u20133337", "journal-title": "J Virol"}, {"key": "20_CR47_20", "doi-asserted-by": "publisher", "first-page": "975", "DOI": "10.1002/cncr.23669", "volume": "113", "author": "CS Higano", "year": "2008", "unstructured": "Higano CS, Corman JM, Smith DC et al (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975\u2013984", "journal-title": "Cancer"}, {"key": "20_CR48_20", "first-page": "1089", "volume": "65", "author": "F Hirano", "year": "2005", "unstructured": "Hirano F, Kaneko K, Tamura H et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089\u20131096", "journal-title": "Cancer Res"}, {"key": "20_CR49_20", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "FS Hodi", "year": "2010", "unstructured": "Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723", "journal-title": "N Engl J Med"}, {"key": "20_CR50_20", "doi-asserted-by": "publisher", "first-page": "1388", "DOI": "10.1093/jnci/djq310", "volume": "102", "author": "A Hoos", "year": "2010", "unstructured": "Hoos A, Eggermont AM, Janetzki S et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388\u20131397", "journal-title": "J Natl Cancer Inst"}, {"key": "20_CR51_20", "unstructured": "Hussain M, Smith,MR, Sweeney C, Corn PG, ElfikyA, GordonMS, HaasNB, Harzstark AL, KurzrockR, LaraP, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, ScheffoldC, Ballinger MD, Schimmoller F, Smith DC (2011) Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 29:(suppl; abstr 4516)", "DOI": "10.1200/jco.2011.29.15_suppl.4516", "doi-asserted-by": "crossref"}, {"key": "20_CR52_20", "doi-asserted-by": "publisher", "first-page": "870", "DOI": "10.1177/00912700122010771", "volume": "41", "author": "JD Iuliucci", "year": "2001", "unstructured": "Iuliucci JD, Oliver SD, Morley S et al (2001) Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41:870\u2013879", "journal-title": "J Clin Pharmacol"}, {"key": "20_CR53_20", "doi-asserted-by": "publisher", "first-page": "133", "DOI": "10.1093/intimm/dxh194", "volume": "17", "author": "Y Iwai", "year": "2005", "unstructured": "Iwai Y, Terawaki S, Honjo T (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17:133\u2013144", "journal-title": "Int Immunol"}, {"key": "20_CR54_20", "doi-asserted-by": "publisher", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "volume": "363", "author": "PW Kantoff", "year": "2010", "unstructured": "Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422", "journal-title": "N Engl J Med"}, {"key": "20_CR55_20", "first-page": "18s", "volume": "28", "author": "WK Kelly", "year": "2010", "unstructured": "Kelly WK, Halabi S, Carducci MA et al (2010) A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 28:18s (suppl; abstr LBA4511)", "journal-title": "J Clin Oncol"}, {"key": "20_CR56_20", "doi-asserted-by": "publisher", "first-page": "1245", "DOI": "10.1517/14712598.7.8.1245", "volume": "7", "author": "LF Langer", "year": "2007", "unstructured": "Langer LF, Clay TM, Morse MA (2007) Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 7:1245\u20131256", "journal-title": "Expert Opin Biol Ther"}, {"key": "20_CR57_20", "doi-asserted-by": "publisher", "first-page": "10528", "DOI": "10.1158/0008-5472.CAN-07-0833", "volume": "67", "author": "N Lapteva", "year": "2007", "unstructured": "Lapteva N, Seethammagari MR, Hanks BA et al (2007) Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 ligation. Cancer Res 67:10528\u201310537", "journal-title": "Cancer Res"}, {"key": "20_CR58_20", "doi-asserted-by": "publisher", "first-page": "4047", "DOI": "10.1200/JCO.2008.19.9968", "volume": "27", "author": "DG McNeel", "year": "2009", "unstructured": "McNeel DG, Dunphy EJ, Davies JG et al (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27:4047\u20134054", "journal-title": "J Clin Oncol"}, {"key": "20_CR59_20", "doi-asserted-by": "publisher", "first-page": "540", "DOI": "10.1200/JCO.2006.07.8097", "volume": "25", "author": "MI Milowsky", "year": "2007", "unstructured": "Milowsky MI, Nanus DM, Kostakoglu L et al (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540\u2013547", "journal-title": "J Clin Oncol"}, {"key": "20_CR60_20", "doi-asserted-by": "publisher", "first-page": "783", "DOI": "10.1111/j.1464-410X.2005.05714.x", "volume": "96", "author": "M Nakabayashi", "year": "2005", "unstructured": "Nakabayashi M, Regan MM, Lifsey D et al (2005) Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 96:783\u2013786", "journal-title": "BJU Int"}, {"key": "20_CR61_20", "doi-asserted-by": "publisher", "first-page": "1392", "DOI": "10.1111/j.1464-410X.2009.08971.x", "volume": "105", "author": "M Nakabayashi", "year": "2010", "unstructured": "Nakabayashi M, Oh WK, Jacobus S et al (2010) Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int 105:1392\u20131396", "journal-title": "BJU Int"}, {"key": "20_CR62_20", "first-page": "10", "volume": "3", "author": "T Nakada", "year": "2003", "unstructured": "Nakada T, Noguchi Y, Satoh S et al (2003) NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 3:10", "journal-title": "Cancer Immun"}, {"key": "20_CR63_20", "doi-asserted-by": "publisher", "first-page": "587", "DOI": "10.1016/S1470-2045(07)70147-X", "volume": "8", "author": "S Nilsson", "year": "2007", "unstructured": "Nilsson S, Franzen L, Parker C et al (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8:587\u2013594", "journal-title": "Lancet Oncol"}, {"key": "20_CR64_20", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1126/science.291.5502.319", "volume": "291", "author": "H Nishimura", "year": "2001", "unstructured": "Nishimura H, Okazaki T, Tanaka Y et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319\u2013322", "journal-title": "Science"}, {"key": "20_CR65_20", "doi-asserted-by": "crossref", "first-page": "2317", "DOI": "10.1038/sj.bjc.6601879", "volume": "90", "author": "A O\u2019Donnell", "year": "2004", "unstructured": "O\u2019Donnell A, Judson I, Dowsett M et al (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317\u20132325", "journal-title": "Br J Cancer"}, {"key": "20_CR66_20", "doi-asserted-by": "publisher", "first-page": "958", "DOI": "10.1158/1078-0432.CCR-06-1974", "volume": "13", "author": "D O\u2019Mahony", "year": "2007", "unstructured": "O\u2019Mahony D, Morris JC, Quinn C et al (2007) A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13:958\u2013964", "journal-title": "Clin Cancer Res"}, {"key": "20_CR67_20", "unstructured": "Ou Y, Michelson MD, Sengel\u00f8v L et al (2011) Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU \u2009+ \u2009P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 29:(suppl; abstr 4515)", "DOI": "10.1200/jco.2011.29.15_suppl.4515", "doi-asserted-by": "crossref"}, {"key": "20_CR68_20", "doi-asserted-by": "publisher", "first-page": "1992", "DOI": "10.1016/S0022-5347(05)66935-2", "volume": "164", "author": "C Palmberg", "year": "2000", "unstructured": "Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992\u20131995", "journal-title": "J Urol"}, {"key": "20_CR69_20", "doi-asserted-by": "publisher", "first-page": "1581", "DOI": "10.1038/nbt1262", "volume": "24", "author": "D Park", "year": "2006", "unstructured": "Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM (2006) An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol 24:1581\u20131590", "journal-title": "Nat Biotechnol"}, {"key": "20_CR70_20", "doi-asserted-by": "publisher", "first-page": "397", "DOI": "10.1038/icb.1997.62", "volume": "75", "author": "S Pasquini", "year": "1997", "unstructured": "Pasquini S, Xiang Z, Wang Y et al (1997) Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol 75:397\u2013401", "journal-title": "Immunol Cell Biol"}, {"key": "20_CR71_20", "doi-asserted-by": "crossref", "first-page": "688", "DOI": "10.1038/sj.bjc.6602019", "volume": "91", "author": "M Pavlenko", "year": "2004", "unstructured": "Pavlenko M, Roos AK, Lundqvist A et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688\u2013694", "journal-title": "Br J Cancer"}, {"key": "20_CR72_20", "doi-asserted-by": "publisher", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "volume": "351", "author": "DP Petrylak", "year": "2004", "unstructured": "Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520", "journal-title": "N Engl J Med"}, {"key": "20_CR73_20", "doi-asserted-by": "publisher", "first-page": "610", "DOI": "10.1038/ncpuro1237", "volume": "5", "author": "AH Reid", "year": "2008", "unstructured": "Reid AH, Attard G, Barrie E, de Bono JS (2008) CYP17 Inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 5:610\u2013620", "journal-title": "Nat Clin Pract Urol"}, {"key": "20_CR74_20", "doi-asserted-by": "publisher", "first-page": "1489", "DOI": "10.1200/JCO.2009.24.6819", "volume": "28", "author": "AH Reid", "year": "2010", "unstructured": "Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489\u20131495", "journal-title": "J Clin Oncol"}, {"key": "20_CR75_20", "doi-asserted-by": "publisher", "first-page": "1655", "DOI": "10.1056/NEJMra030831", "volume": "350", "author": "GD Roodman", "year": "2004", "unstructured": "Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664", "journal-title": "N Engl J Med"}, {"key": "20_CR76_20", "doi-asserted-by": "publisher", "first-page": "556", "DOI": "10.1002/cncr.22811", "volume": "110", "author": "JE Rosenberg", "year": "2007", "unstructured": "Rosenberg JE, Weinberg VK, Kelly WK et al (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110:556\u2013563", "journal-title": "Cancer"}, {"key": "20_CR77_20", "doi-asserted-by": "publisher", "first-page": "521", "DOI": "10.1002/cncr.23195", "volume": "112", "author": "RW Ross", "year": "2008", "unstructured": "Ross RW, Beer TM, Jacobus S et al (2008) A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112:521\u2013526", "journal-title": "Cancer"}, {"key": "20_CR78_20", "doi-asserted-by": "publisher", "first-page": "2030", "DOI": "10.1158/1078-0432.CCR-06-2344", "volume": "13", "author": "CJ Ryan", "year": "2007", "unstructured": "Ryan CJ (2007) Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 13:2030\u20132037", "journal-title": "Clin Cancer Res"}, {"key": "20_CR79_20", "doi-asserted-by": "publisher", "first-page": "1481", "DOI": "10.1200/JCO.2009.24.1281", "volume": "28", "author": "CJ Ryan", "year": "2010", "unstructured": "Ryan CJ, Smith MR, Fong L et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481\u20131488: official journal of the American Society of Clinical Oncology", "journal-title": "J Clin Oncol"}, {"key": "20_CR80_20", "doi-asserted-by": "publisher", "first-page": "879", "DOI": "10.1093/jnci/djh141", "volume": "96", "author": "F Saad", "year": "2004", "unstructured": "Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882", "journal-title": "J Natl Cancer Inst"}, {"key": "20_CR81_20", "doi-asserted-by": "crossref", "first-page": "2928", "DOI": "10.1200/JCO.1997.15.8.2928", "volume": "15", "author": "HI Scher", "year": "1997", "unstructured": "Scher HI, Liebertz C, Kelly WK et al (1997) Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15:2928\u20132938", "journal-title": "J Clin Oncol"}, {"key": "20_CR82_20", "doi-asserted-by": "publisher", "first-page": "1148", "DOI": "10.1200/JCO.2007.12.4487", "volume": "26", "author": "HI Scher", "year": "2008", "unstructured": "Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159", "journal-title": "J Clin Oncol"}, {"key": "20_CR83_20", "doi-asserted-by": "publisher", "first-page": "1437", "DOI": "10.1016/S0140-6736(10)60172-9", "volume": "375", "author": "HI Scher", "year": "2010", "unstructured": "Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet 375:1437\u20131446", "journal-title": "Lancet"}, {"key": "20_CR84_20", "doi-asserted-by": "publisher", "first-page": "2191", "DOI": "10.1200/JCO.2010.32.8815", "volume": "29", "author": "HI Scher", "year": "2011", "unstructured": "Scher HI, Jia X, Chi K et al (2011a) Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29:2191\u20132198", "journal-title": "J Clin Oncol"}, {"key": "20_CR85_20", "unstructured": "Scher HI, Heller G, Molina A, Kheoh TS, Attard G, Moreira J et al (2011) Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response \u00adbiomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 29:(suppl; abstr LBA4517^)", "DOI": "10.1200/jco.2011.29.15_suppl.lba4517", "doi-asserted-by": "crossref"}, {"key": "20_CR86_20", "doi-asserted-by": "publisher", "first-page": "2023", "DOI": "10.1158/1078-0432.CCR-06-2701", "volume": "13", "author": "DR Shaffer", "year": "2007", "unstructured": "Shaffer DR, Leversha MA, Danila DC et al (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13:2023\u20132029: an official journal of the American Association for Cancer Research", "journal-title": "Clin Cancer Res"}, {"key": "20_CR87_20", "unstructured": "Sieber P, Smith RM, Saad F et al (2011) Denosumab treatment for prolonging bone metastasis-free survival in men with castrate-resistant prostate cancer. In: American Urological Association (AUA) annual meeting, Washington, DC, 14\u201319 May 2011"}, {"key": "20_CR88_20", "doi-asserted-by": "publisher", "first-page": "1428", "DOI": "10.1002/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T", "volume": "76", "author": "EJ Small", "year": "1995", "unstructured": "Small EJ, Srinivas S (1995) The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76:1428\u20131434", "journal-title": "Cancer"}, {"key": "20_CR89_20", "doi-asserted-by": "publisher", "first-page": "1025", "DOI": "10.1200/JCO.2004.06.037", "volume": "22", "author": "EJ Small", "year": "2004", "unstructured": "Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025\u20131033: official journal of the American Society of Clinical Oncology", "journal-title": "J Clin Oncol"}, {"key": "20_CR90_20", "doi-asserted-by": "publisher", "first-page": "3089", "DOI": "10.1200/JCO.2005.04.5252", "volume": "24", "author": "EJ Small", "year": "2006", "unstructured": "Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089\u20133094", "journal-title": "J Clin Oncol"}, {"key": "20_CR91_20", "doi-asserted-by": "publisher", "first-page": "3883", "DOI": "10.1158/1078-0432.CCR-06-2937", "volume": "13", "author": "EJ Small", "year": "2007", "unstructured": "Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13:3883\u20133891", "journal-title": "Clin Cancer Res"}, {"key": "20_CR92_20", "unstructured": "Small E, Demkow T, Gerritsen WR, et al (2009) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: Proceedings genitourinary cancer symposium, Orlando, Feb 2009, abstract 7"}, {"key": "20_CR93_20", "doi-asserted-by": "publisher", "first-page": "591", "DOI": "10.1146/annurev.immunol.021908.132706", "volume": "27", "author": "JE Smith-Garvin", "year": "2009", "unstructured": "Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. Annu Rev Immunol 27:591\u2013619", "journal-title": "Annu Rev Immunol"}, {"key": "20_CR94_20", "first-page": "25", "volume": "12", "author": "G Sonpavde", "year": "2010", "unstructured": "Sonpavde G, Slawin KM, Spencer DM, Levitt JM (2010) Emerging vaccine therapy approaches for prostate cancer. Rev Urol 12:25\u201334, Winter", "journal-title": "Rev Urol"}, {"key": "20_CR95_20", "unstructured": "Sonpavde G, Matveev V, Burke JM et al (2011) A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 29:(suppl; abstr 4528)", "DOI": "10.1200/jco.2011.29.15_suppl.4528", "doi-asserted-by": "crossref"}, {"key": "20_CR97_20", "doi-asserted-by": "publisher", "first-page": "2815", "DOI": "10.1158/0008-5472.CAN-05-4000", "volume": "66", "author": "M Stanbrough", "year": "2006", "unstructured": "Stanbrough M, Bubley GJ, Ross K et al (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815\u20132825", "journal-title": "Cancer Res"}, {"key": "20_CR98_20", "doi-asserted-by": "publisher", "first-page": "4434", "DOI": "10.1158/0008-5472.CAN-08-3605", "volume": "69", "author": "MP Steinkamp", "year": "2009", "unstructured": "Steinkamp MP, O\u2019Mahony OA, Brogley M et al (2009) Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69:4434\u20134442", "journal-title": "Cancer Res"}, {"key": "20_CR99_20", "doi-asserted-by": "publisher", "first-page": "1264", "DOI": "10.1093/annonc/mdn784", "volume": "20", "author": "CN Sternberg", "year": "2009", "unstructured": "Sternberg CN, Dumez H, Van Poppel H et al (2009a) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20:1264\u20131269", "journal-title": "Ann Oncol"}, {"key": "20_CR100_20", "doi-asserted-by": "publisher", "first-page": "5431", "DOI": "10.1200/JCO.2008.20.1228", "volume": "27", "author": "CN Sternberg", "year": "2009", "unstructured": "Sternberg CN, Petrylak DP, Sartor O et al (2009b) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27:5431\u20135438", "journal-title": "J Clin Oncol"}, {"key": "20_CR101_20", "doi-asserted-by": "publisher", "first-page": "1075", "DOI": "10.1002/cncr.24795", "volume": "116", "author": "ST Tagawa", "year": "2010", "unstructured": "Tagawa ST, Beltran H, Vallabhajosula S et al (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116:1075\u20131083", "journal-title": "Cancer"}, {"key": "20_CR102_20", "doi-asserted-by": "publisher", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "volume": "351", "author": "IF Tannock", "year": "2004", "unstructured": "Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512", "journal-title": "N Engl J Med"}, {"key": "20_CR103_20", "doi-asserted-by": "publisher", "first-page": "2673", "DOI": "10.1200/JCO.2003.11.102", "volume": "21", "author": "ME Taplin", "year": "2003", "unstructured": "Taplin ME, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673\u20132678", "journal-title": "J Clin Oncol"}, {"key": "20_CR104_20", "doi-asserted-by": "publisher", "first-page": "787", "DOI": "10.1126/science.1168175", "volume": "324", "author": "C Tran", "year": "2009", "unstructured": "Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790", "journal-title": "Science"}, {"key": "20_CR105_20", "doi-asserted-by": "publisher", "first-page": "1825", "DOI": "10.1007/s00262-010-0908-z", "volume": "59", "author": "MM Luijn van", "year": "2010", "unstructured": "van Luijn MM, Chamuleau ME, Ressing ME et al (2010) Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother 59:1825\u20131838", "journal-title": "Cancer Immunol Immunother"}, {"key": "20_CR106_20", "doi-asserted-by": "publisher", "first-page": "2348", "DOI": "10.1158/1535-7163.MCT-08-0230", "volume": "7", "author": "T Vasaitis", "year": "2008", "unstructured": "Vasaitis T (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17[alpha]-hydroxylase/17,20-lyase inhibitor 3[beta]-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7:2348\u20132357", "journal-title": "Mol Cancer Ther"}, {"key": "20_CR107_20", "unstructured": "Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J Biomed Biotechnol 2010. doi:\n                10.1155/2010/596432", "DOI": "10.1155/2010/596432", "doi-asserted-by": "publisher"}, {"key": "20_CR108_20", "doi-asserted-by": "publisher", "first-page": "4309", "DOI": "10.1158/0008-5472.CAN-08-4102", "volume": "69", "author": "S Wada", "year": "2009", "unstructured": "Wada S, Yoshimura K, Hipkiss EL et al (2009) Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 69:4309\u20134318", "journal-title": "Cancer Res"}, {"key": "20_CR109_20", "doi-asserted-by": "publisher", "first-page": "5246", "DOI": "10.1073/pnas.95.9.5246", "volume": "95", "author": "YE Whang", "year": "1998", "unstructured": "Whang YE, Wu X, Suzuki H et al (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95:5246\u20135250", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "20_CR110_20", "doi-asserted-by": "publisher", "first-page": "7412", "DOI": "10.1158/1078-0432.CCR-09-1624", "volume": "15", "author": "JD Wolchok", "year": "2009", "unstructured": "Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420", "journal-title": "Clin Cancer Res"}, {"key": "20_CR111_20", "doi-asserted-by": "publisher", "first-page": "3964", "DOI": "10.1073/pnas.061507398", "volume": "98", "author": "G Zeng", "year": "2001", "unstructured": "Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964\u20133969", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "20_CR112_20", "first-page": "3630", "volume": "62", "author": "G Zeng", "year": "2002", "unstructured": "Zeng G, Li Y, El-Gamil M et al (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630\u20133635", "journal-title": "Cancer Res"}], "container-title": ["Management of Prostate Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-642-27597-5_20", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 1]], "date-time": "2019-05-01T13:06:08Z", "timestamp": 1556715968000}, "score": 20.956541, "issued": {"date-parts": [[2012]]}, "ISBN": ["9783642275968", "9783642275975"], "references-count": 108, "URL": "http://dx.doi.org/10.1007/978-3-642-27597-5_20", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T20:13:14Z", "timestamp": 1575490394239}, "reference-count": 70, "publisher": "Wiley", "issue": "33", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 442, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Adv. Funct. Mater."], "published-print": {"date-parts": [[2014, 9]]}, "DOI": "10.1002/adfm.201304312", "type": "journal-article", "created": {"date-parts": [[2014, 6, 16]], "date-time": "2014-06-16T22:32:16Z", "timestamp": 1402957936000}, "page": "5202-5210", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Enzyme Prodrug Therapy Engineered into Biomaterials"], "prefix": "10.1002", "volume": "24", "author": [{"given": "Ana C.", "family": "Mendes", "sequence": "first", "affiliation": [{"name": "Department of Chemistry; Aarhus University; Aarhus 8000 Denmark"}]}, {"given": "Alexander N.", "family": "Zelikin", "sequence": "additional", "affiliation": [{"name": "Department of Chemistry; Aarhus University; Aarhus 8000 Denmark"}, {"name": "iNano Interdisciplinary Nanoscience Centre; Aarhus University; Aarhus 8000 Denmark"}]}], "member": "311", "published-online": {"date-parts": [[2014, 6, 16]]}, "reference": [{"key": "10.1002/adfm.201304312-BIB0001|adfm201304312-cit-0001", "author": "Springer", "volume": "26", "first-page": "151", "year": "1997", "journal-title": "Adv. Drug Deliv. Rev.", "DOI": "10.1016/S0169-409X(97)00032-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0002|adfm201304312-cit-0002", "author": "Schellmann", "volume": "10", "first-page": "887", "year": "2010", "journal-title": "Mini Rev. Med. Chem.", "DOI": "10.2174/138955710792007196", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0003|adfm201304312-cit-0003", "author": "Satchi", "volume": "85", "first-page": "1070", "year": "2001", "journal-title": "Brit. J. Cancer", "DOI": "10.1054/bjoc.2001.2026", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0004|adfm201304312-cit-0004", "author": "Springer", "volume": "465", "first-page": "403", "year": "2000", "journal-title": "Adv. Exp. Med. Biol.", "DOI": "10.1007/0-306-46817-4_35", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0005|adfm201304312-cit-0005", "author": "Huber", "volume": "716", "first-page": "104", "year": "1994", "journal-title": "Ann. NY Acad. Sci.", "DOI": "10.1111/j.1749-6632.1994.tb21706.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0006|adfm201304312-cit-0006", "author": "Nawa", "volume": "8", "first-page": "232", "year": "2008", "journal-title": "Anti-Cancer Agent ME", "DOI": "10.2174/187152008783497000", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0007|adfm201304312-cit-0007", "author": "Niculescu-Duvaz", "volume": "9", "first-page": "4", "year": "1998", "journal-title": "Bioconjugate Chem.", "DOI": "10.1021/bc970116t", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0008|adfm201304312-cit-0008", "author": "Lehouritis", "volume": "170", "first-page": "120", "year": "2013", "journal-title": "J. Controlled Release", "DOI": "10.1016/j.jconrel.2013.05.005", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0009|adfm201304312-cit-0009", "author": "Mullard", "volume": "12", "first-page": "329", "year": "2013", "journal-title": "Nat. Rev. Drug Discov.", "DOI": "10.1038/nrd4009", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0010|adfm201304312-cit-0010", "author": "Duncan", "volume": "2", "first-page": "347", "year": "2003", "journal-title": "Nat. Rev. Drug Discov.", "DOI": "10.1038/nrd1088", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0011|adfm201304312-cit-0011", "author": "Duncan", "volume": "6", "first-page": "688", "year": "2006", "journal-title": "Nat. Rev. Cancer", "DOI": "10.1038/nrc1958", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0012|adfm201304312-cit-0012", "author": "Fejerskov", "volume": "4", "first-page": "4981", "year": "2012", "journal-title": "ACS Appl. Mater. Inter.", "DOI": "10.1021/am3013467", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0013|adfm201304312-cit-0013", "author": "Fejerskov", "volume": "7", "first-page": "e49619", "year": "2012", "journal-title": "PLOS One", "DOI": "10.1371/journal.pone.0049619", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0014|adfm201304312-cit-0014", "author": "Andreasen", "volume": "6", "first-page": "4131", "year": "2014", "journal-title": "Nanoscale", "DOI": "10.1039/c3nr05999e", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0015|adfm201304312-cit-0015", "author": "Fejerskov", "volume": "10", "first-page": "1314", "year": "2014", "journal-title": "Small", "DOI": "10.1002/smll.201303101", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0016|adfm201304312-cit-0016", "author": "Fejerskov", "volume": "29", "first-page": "344", "year": "2012", "journal-title": "Langmuir", "DOI": "10.1021/la3040903", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0017|adfm201304312-cit-0017", "author": "Uhrich", "volume": "99", "first-page": "3181", "year": "1999", "journal-title": "Chem. Rev.", "DOI": "10.1021/cr940351u", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0018|adfm201304312-cit-0018", "author": "Acharya", "volume": "58", "first-page": "387", "year": "2006", "journal-title": "Adv. Drug Deliv. Rev.", "DOI": "10.1016/j.addr.2006.01.016", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0019|adfm201304312-cit-0019", "author": "Alves", "volume": "11", "first-page": "1293", "year": "2011", "journal-title": "Macromol. Biosci.", "DOI": "10.1002/mabi.201100145", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0020|adfm201304312-cit-0020", "author": "Baker", "volume": "100B", "first-page": "1451", "year": "2012", "journal-title": "J. Biomed. Mater. Res. B", "DOI": "10.1002/jbm.b.32694", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0021|adfm201304312-cit-0021", "author": "Carter", "volume": "11", "first-page": "541", "year": "2009", "journal-title": "HPB", "DOI": "10.1111/j.1477-2574.2009.00071.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0022|adfm201304312-cit-0022", "author": "Lupattelli", "volume": "54", "first-page": "136", "year": "2005", "journal-title": "Eur. J. Radiol.", "DOI": "10.1016/j.ejrad.2004.04.006", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0023|adfm201304312-cit-0023", "author": "Chaouat", "volume": "18", "first-page": "2855", "year": "2008", "journal-title": "Adv. Funct. Mater.", "DOI": "10.1002/adfm.200701261", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0024|adfm201304312-cit-0024", "author": "Greiner", "volume": "46", "first-page": "5670", "year": "2007", "journal-title": "Angew. Chem. Int. Edit.", "DOI": "10.1002/anie.200604646", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0025|adfm201304312-cit-0025", "author": "Ren", "volume": "66", "first-page": "1559", "year": "2006", "journal-title": "React. Funct. Polym.", "DOI": "10.1016/j.reactfunctpolym.2006.05.005", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0026|adfm201304312-cit-0026", "author": "Wang", "volume": "309", "first-page": "73", "year": "2008", "journal-title": "J. Membrane Sci.", "DOI": "10.1016/j.memsci.2007.10.008", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0027|adfm201304312-cit-0027", "author": "Wu", "volume": "250", "first-page": "167", "year": "2005", "journal-title": "J. Membrane Sci.", "DOI": "10.1016/j.memsci.2004.10.024", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0028|adfm201304312-cit-0028", "author": "Zeng", "volume": "6", "first-page": "1484", "year": "2005", "journal-title": "Biomacromolecules", "DOI": "10.1021/bm0492576", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0029|adfm201304312-cit-0029", "author": "Mickova", "volume": "13", "first-page": "952", "year": "2012", "journal-title": "Biomacromolecules", "DOI": "10.1021/bm2018118", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0030|adfm201304312-cit-0030", "author": "Heath", "volume": "59", "first-page": "251", "year": "2008", "journal-title": "Annu. Rev. Med.", "DOI": "10.1146/annurev.med.59.061506.185523", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0031|adfm201304312-cit-0031", "author": "Xu", "volume": "7", "first-page": "3314", "year": "2001", "journal-title": "Clin. Cancer Res."}, {"key": "10.1002/adfm.201304312-BIB0032|adfm201304312-cit-0032", "author": "Cuzick", "volume": "10", "first-page": "501", "year": "2009", "journal-title": "Lancet Oncol.", "DOI": "10.1016/S1470-2045(09)70035-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0033|adfm201304312-cit-0033", "author": "Ulrich", "volume": "6", "first-page": "130", "year": "2006", "journal-title": "Nat. Rev. Cancer", "DOI": "10.1038/nrc1801", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0034|adfm201304312-cit-0034", "author": "Pereg", "volume": "258", "first-page": "115", "year": "2005", "journal-title": "J. Intern. Med.", "DOI": "10.1111/j.1365-2796.2005.01519.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0035|adfm201304312-cit-0035", "author": "Tan", "volume": "1", "first-page": "867", "year": "2002", "journal-title": "Nat. Rev. Drug Discov.", "DOI": "10.1038/nrd937", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0036|adfm201304312-cit-0036", "author": "Drury", "volume": "24", "first-page": "4337", "year": "2003", "journal-title": "Biomaterials", "DOI": "10.1016/S0142-9612(03)00340-5", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0037|adfm201304312-cit-0037", "author": "Hamidi", "volume": "60", "first-page": "1638", "year": "2008", "journal-title": "Adv. Drug Deliv. Rev.", "DOI": "10.1016/j.addr.2008.08.002", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0038|adfm201304312-cit-0038", "author": "Hoare", "volume": "49", "first-page": "1993", "year": "2008", "journal-title": "Polymer", "DOI": "10.1016/j.polymer.2008.01.027", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0039|adfm201304312-cit-0039", "author": "Khademhosseini", "volume": "28", "first-page": "5087", "year": "2007", "journal-title": "Biomaterials", "DOI": "10.1016/j.biomaterials.2007.07.021", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0040|adfm201304312-cit-0040", "author": "Lee", "volume": "101", "first-page": "1869", "year": "2001", "journal-title": "Chem. Rev.", "DOI": "10.1021/cr000108x", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0041|adfm201304312-cit-0041", "author": "Slaughter", "volume": "21", "first-page": "3307", "year": "2009", "journal-title": "Adv. Mater.", "DOI": "10.1002/adma.200802106", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0042|adfm201304312-cit-0042", "author": "Liechty", "volume": "1", "first-page": "149", "year": "2010", "journal-title": "Annu. Rev. Chem. Biomol.", "DOI": "10.1146/annurev-chembioeng-073009-100847", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0043|adfm201304312-cit-0043", "author": "Aydin", "first-page": "291", "year": "2012", "volume-title": "Intelligent Surfaces in Biotechnology", "DOI": "10.1002/9781118181249.ch8", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0044|adfm201304312-cit-0044", "author": "Malmstrom", "volume": "10", "first-page": "686", "year": "2010", "journal-title": "Nano Lett.", "DOI": "10.1021/nl903875r", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0045|adfm201304312-cit-0045", "author": "Alves", "volume": "6", "first-page": "2208", "year": "2010", "journal-title": "Small", "DOI": "10.1002/smll.201000233", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0046|adfm201304312-cit-0046", "author": "Hosta-Rigau", "volume": "1", "first-page": "791", "year": "2012", "journal-title": "Adv. Healthcare Mater.", "DOI": "10.1002/adhm.201200092", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0047|adfm201304312-cit-0047", "author": "Chong", "volume": "9", "first-page": "942", "year": "2013", "journal-title": "Small", "DOI": "10.1002/smll.201201774", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0048|adfm201304312-cit-0048", "author": "Jensen", "volume": "5", "first-page": "6758", "year": "2013", "journal-title": "Nanoscale", "DOI": "10.1039/c3nr01662e", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0049|adfm201304312-cit-0049", "author": "Kryger", "volume": "49", "first-page": "2643", "year": "2013", "journal-title": "Chem. Commun.", "DOI": "10.1039/c3cc00315a", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0050|adfm201304312-cit-0050", "author": "Smith", "year": "2014", "journal-title": "Adv. Healthcare Mater."}, {"key": "10.1002/adfm.201304312-BIB0051|adfm201304312-cit-0051", "author": "Wohl", "volume": "14", "first-page": "3916", "year": "2013", "journal-title": "Biomacromolecules", "DOI": "10.1021/bm401048s", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0052|adfm201304312-cit-0052", "author": "Pommier", "volume": "6", "first-page": "789", "year": "2006", "journal-title": "Nat. Rev. Cancer", "DOI": "10.1038/nrc1977", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0053|adfm201304312-cit-0053", "author": "Longley", "volume": "3", "first-page": "330", "year": "2003", "journal-title": "Nat. Rev. Cancer", "DOI": "10.1038/nrc1074", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0054|adfm201304312-cit-0054", "author": "Kunnumakkara", "volume": "269", "first-page": "199", "year": "2008", "journal-title": "Cancer Lett.", "DOI": "10.1016/j.canlet.2008.03.009", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0055|adfm201304312-cit-0055", "author": "Lu", "volume": "17", "first-page": "1101", "year": "1999", "journal-title": "Nat. Biotechnol.", "DOI": "10.1038/15085", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0056|adfm201304312-cit-0056", "author": "Oberoi", "volume": "153", "first-page": "64", "year": "2011", "journal-title": "J. Controlled Release", "DOI": "10.1016/j.jconrel.2011.03.028", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0057|adfm201304312-cit-0057", "author": "Solomon", "volume": "10", "first-page": "793", "year": "1999", "journal-title": "J. Vasc. Interv. Radiol.", "DOI": "10.1016/S1051-0443(99)70117-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0058|adfm201304312-cit-0058", "author": "Surh", "volume": "480-481", "first-page": "243", "year": "2001", "journal-title": "Mutat. Res. - Fund. Mol. M.", "DOI": "10.1016/S0027-5107(01)00183-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0059|adfm201304312-cit-0059", "author": "Moorcroft", "volume": "54", "first-page": "785", "year": "2001", "journal-title": "Talanta", "DOI": "10.1016/S0039-9140(01)00323-X", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0060|adfm201304312-cit-0060", "author": "Grayson", "volume": "2", "first-page": "767", "year": "2003", "journal-title": "Nat. Mater.", "DOI": "10.1038/nmat998", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0061|adfm201304312-cit-0061", "author": "Chou", "volume": "58", "first-page": "621", "year": "2006", "journal-title": "Pharmacol. Rev.", "DOI": "10.1124/pr.58.3.10", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0062|adfm201304312-cit-0062", "author": "De Clercq", "volume": "6", "first-page": "1001", "year": "2007", "journal-title": "Nat. Rev. Drug. Discov.", "DOI": "10.1038/nrd2424", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0063|adfm201304312-cit-0063", "author": "Deeks", "volume": "12", "first-page": "607", "year": "2012", "journal-title": "Nat. Rev. Immunol.", "DOI": "10.1038/nri3262", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0064|adfm201304312-cit-0064", "author": "Shankarappa", "volume": "109", "first-page": "17555", "year": "2012", "journal-title": "Proc. Natl. Acad. Sci. USA", "DOI": "10.1073/pnas.1214634109", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0065|adfm201304312-cit-0065", "author": "Al-Lazikani", "volume": "30", "first-page": "679", "year": "2012", "journal-title": "Nat. Biotechnol.", "DOI": "10.1038/nbt.2284", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0066|adfm201304312-cit-0066", "author": "Ben", "volume": "11", "first-page": "179", "year": "2011", "journal-title": "Int. Immunopharm.", "DOI": "10.1016/j.intimp.2010.11.013", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0067|adfm201304312-cit-0067", "author": "Walker", "volume": "272", "first-page": "16679", "year": "1996", "journal-title": "J. Biol. Chem.", "DOI": "10.1074/jbc.272.26.16679", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0068|adfm201304312-cit-0068", "author": "Karaman", "volume": "42", "first-page": "79", "year": "2011", "journal-title": "Arch. Med. Res.", "DOI": "10.1016/j.arcmed.2011.01.011", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0069|adfm201304312-cit-0069", "author": "Zhao", "volume": "10", "first-page": "7994", "year": "2004", "journal-title": "Clin. Cancer Res.", "DOI": "10.1158/1078-0432.CCR-04-1087", "doi-asserted-by": "crossref"}, {"key": "10.1002/adfm.201304312-BIB0070|adfm201304312-cit-0070", "author": "Chou", "volume": "4", "first-page": "450", "year": "1983", "journal-title": "Trends Pharm. Sci.", "DOI": "10.1016/0165-6147(83)90490-X", "doi-asserted-by": "crossref"}], "container-title": ["Advanced Functional Materials"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fadfm.201304312", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/adfm.201304312", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T09:30:06Z", "timestamp": 1533115806000}, "score": 20.726843, "issued": {"date-parts": [[2014, 6, 16]]}, "references-count": 70, "journal-issue": {"published-print": {"date-parts": [[2014, 9]]}, "issue": "33"}, "URL": "http://dx.doi.org/10.1002/adfm.201304312", "relation": {"cites": []}, "ISSN": ["1616-301X"], "issn-type": [{"value": "1616-301X", "type": "print"}], "subject": ["Electrochemistry", "Electronic, Optical and Magnetic Materials", "Condensed Matter Physics", "Biomaterials"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:49:40Z", "timestamp": 1574488180644}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 4, 1]]}, "DOI": "10.1158/1078-0432.tcme10-pl5-1", "type": "proceedings-article", "created": {"date-parts": [[2011, 1, 10]], "date-time": "2011-01-10T18:45:36Z", "timestamp": 1294685136000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract PL5-1: Targeting the nexus of heat shock and metabolic stress responses in cancer"], "prefix": "10.1158", "author": [{"given": "Kapil N.", "family": "Bhalla", "sequence": "first", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2016, 2, 2]]}, "event": {"name": "Abstracts: AACR International Conference on Translational Cancer Medicine--; Mar 21\u201324, 2010; Amsterdam, The Netherlands"}, "container-title": ["Targets, Targeted Therapies, and Resistance"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.TCME10-PL5-1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T17:58:52Z", "timestamp": 1557424732000}, "score": 19.546833, "issued": {"date-parts": [[2010, 4, 1]]}, "references-count": 0, "alternative-id": ["10.1158/1078-0432.TCME10-PL5-1"], "URL": "http://dx.doi.org/10.1158/1078-0432.tcme10-pl5-1"}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T14:18:37Z", "timestamp": 1574691517980}, "reference-count": 0, "publisher": "CLOCKSS Archive", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["MD Conference Express"], "published-print": {"date-parts": [[2014, 6, 1]]}, "DOI": "10.1177/155989771403013", "type": "journal-article", "created": {"date-parts": [[2015, 4, 17]], "date-time": "2015-04-17T00:23:15Z", "timestamp": 1429230195000}, "page": "20-21", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeted Therapies for NSCLC"], "prefix": "10.13030", "volume": "14", "author": [{"given": "N.", "family": "Parry", "sequence": "first", "affiliation": []}, {"given": "R.", "family": "Dziadziuszko", "sequence": "additional", "affiliation": []}], "member": "5187", "container-title": ["MD Conference Express"], "language": "en", "deposited": {"date-parts": [[2019, 4, 1]], "date-time": "2019-04-01T19:59:11Z", "timestamp": 1554148751000}, "score": 19.546833, "issued": {"date-parts": [[2014, 6, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2014, 6, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1177/155989771403013", "ISSN": ["1559-8977", "2155-756X"], "issn-type": [{"value": "1559-8977", "type": "print"}, {"value": "2155-756X", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:26:15Z", "timestamp": 1575185175088}, "reference-count": 22, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2004, 2, 1]], "date-time": "2004-02-01T00:00:00Z", "timestamp": 1075593600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Seminars in Oncology"], "published-print": {"date-parts": [[2004, 2]]}, "DOI": "10.1053/j.seminoncol.2004.01.003", "type": "journal-article", "created": {"date-parts": [[2005, 11, 3]], "date-time": "2005-11-03T13:58:14Z", "timestamp": 1131026294000}, "page": "21-27", "source": "Crossref", "is-referenced-by-count": 24, "title": ["Opportunities and challenges in the development of targeted therapies"], "prefix": "10.1053", "volume": "31", "author": [{"given": "Gabriel N", "family": "Hortobagyi", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Seminars in Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0093775404000211?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0093775404000211?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 4]], "date-time": "2019-04-04T04:28:01Z", "timestamp": 1554352081000}, "score": 19.546833, "issued": {"date-parts": [[2004, 2]]}, "references-count": 22, "alternative-id": ["S0093775404000211"], "URL": "http://dx.doi.org/10.1053/j.seminoncol.2004.01.003", "ISSN": ["0093-7754"], "issn-type": [{"value": "0093-7754", "type": "print"}], "subject": ["Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 7]], "date-time": "2019-12-07T06:10:08Z", "timestamp": 1575699008275}, "publisher-location": "Cham", "reference-count": 65, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783030244231", "type": "print"}, {"value": "9783030244248", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019]]}, "DOI": "10.1007/978-3-030-24424-8_7", "type": "book-chapter", "created": {"date-parts": [[2019, 9, 13]], "date-time": "2019-09-13T14:02:58Z", "timestamp": 1568383378000}, "page": "155-179", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs"], "prefix": "10.1007", "author": [{"given": "Anthony N.", "family": "Audino", "sequence": "first", "affiliation": []}, {"given": "Mitchell S.", "family": "Cairo", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2019, 9, 14]]}, "reference": [{"issue": "5", "key": "7_CR1", "doi-asserted-by": "publisher", "first-page": "2499", "DOI": "10.3892/or.2016.4660", "volume": "35", "author": "Y Yuan", "year": "2016", "unstructured": "Yuan Y, Jiang YC, Sun CK, Chen QM. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 2016;35(5):2499\u2013515.", "journal-title": "Oncol Rep"}, {"key": "7_CR2", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.1016/j.intimp.2017.03.015", "volume": "46", "author": "Q Wang", "year": "2017", "unstructured": "Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210\u20139.", "journal-title": "Int Immunopharmacol"}, {"issue": "6230", "key": "7_CR3", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.1126/science.aaa6204", "volume": "348", "author": "JA Joyce", "year": "2015", "unstructured": "Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.", "journal-title": "Science"}, {"issue": "1", "key": "7_CR4", "doi-asserted-by": "publisher", "first-page": "7", "DOI": "10.1016/j.canlet.2015.07.039", "volume": "368", "author": "L Hui", "year": "2015", "unstructured": "Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7\u201313.", "journal-title": "Cancer Lett"}, {"issue": "7", "key": "7_CR5", "doi-asserted-by": "publisher", "first-page": "794", "DOI": "10.3324/haematol.2015.132761", "volume": "101", "author": "S Vardhana", "year": "2016", "unstructured": "Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica. 2016;101(7):794\u2013802.", "journal-title": "Haematologica"}, {"issue": "4", "key": "7_CR6", "doi-asserted-by": "publisher", "first-page": "707", "DOI": "10.1016/j.cell.2017.01.017", "volume": "168", "author": "P Sharma", "year": "2017", "unstructured": "Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.", "journal-title": "Cell"}, {"issue": "1", "key": "7_CR7", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1016/j.immuni.2014.06.010", "volume": "41", "author": "R Noy", "year": "2014", "unstructured": "Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49\u201361.", "journal-title": "Immunity"}, {"key": "7_CR8", "first-page": "1841", "volume-title": "Nathan and Oski\u2019s hematology of infancy and childhood", "author": "SH Orkin", "year": "2009", "unstructured": "Orkin SH, Nathan DG. Nathan and Oski\u2019s hematology of infancy and childhood, vol. xxvi. 7th ed. Philadelphia: Saunders/Elsevier; 2009. p. 1841.", "edition": "7"}, {"key": "7_CR9", "doi-asserted-by": "publisher", "first-page": "601", "DOI": "10.1146/annurev.immunol.23.021704.115737", "volume": "23", "author": "EV Rothenberg", "year": "2005", "unstructured": "Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol. 2005;23:601\u201349.", "journal-title": "Annu Rev Immunol"}, {"issue": "Suppl 1", "key": "7_CR10", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1007/BF00736825", "volume": "5", "author": "CE Grossi", "year": "1991", "unstructured": "Grossi CE, Favre A, Giunta M, Corte G. T cell differentiation in the thymus. Cytotechnology. 1991;5(Suppl 1):113\u20136.", "journal-title": "Cytotechnology"}, {"issue": "1", "key": "7_CR11", "first-page": "91", "volume": "1", "author": "C Viret", "year": "1999", "unstructured": "Viret C, Janeway CA Jr. MHC and T cell development. Rev Immunogenet. 1999;1(1):91\u2013104.", "journal-title": "Rev Immunogenet"}, {"issue": "2", "key": "7_CR12", "doi-asserted-by": "publisher", "first-page": "301", "DOI": "10.1016/0092-8674(88)90053-0", "volume": "55", "author": "A Veillette", "year": "1988", "unstructured": "Veillette A, Bookman MA, Horak EM, Bolen JB. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell. 1988;55(2):301\u20138.", "journal-title": "Cell"}, {"issue": "5", "key": "7_CR13", "doi-asserted-by": "publisher", "first-page": "758", "DOI": "10.1067/mai.2002.124259", "volume": "109", "author": "AE Nel", "year": "2002", "unstructured": "Nel AE. T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immun. 2002;109(5):758\u201370.", "journal-title": "J Allergy Clin Immun"}, {"issue": "11", "key": "7_CR14", "doi-asserted-by": "publisher", "first-page": "880", "DOI": "10.1038/nrc2250", "volume": "7", "author": "MP Colombo", "year": "2007", "unstructured": "Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7(11):880\u20137.", "journal-title": "Nat Rev Cancer"}, {"issue": "1", "key": "7_CR15", "doi-asserted-by": "publisher", "first-page": "25", "DOI": "10.1189/jlb.1212621", "volume": "94", "author": "AM Intlekofer", "year": "2013", "unstructured": "Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25\u201339.", "journal-title": "J Leukoc Biol"}, {"issue": "1", "key": "7_CR16", "doi-asserted-by": "publisher", "first-page": "30", "DOI": "10.3324/haematol.2016.150656", "volume": "102", "author": "I Hude", "year": "2017", "unstructured": "Hude I, Sasse S, Engert A, Brockelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica. 2017;102(1):30\u201342.", "journal-title": "Haematologica"}, {"issue": "6127", "key": "7_CR17", "doi-asserted-by": "publisher", "first-page": "267", "DOI": "10.1038/328267a0", "volume": "328", "author": "JF Brunet", "year": "1987", "unstructured": "Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily\u2014CTLA-4. Nature. 1987;328(6127):267\u201370.", "journal-title": "Nature"}, {"issue": "5256", "key": "7_CR18", "doi-asserted-by": "publisher", "first-page": "1734", "DOI": "10.1126/science.271.5256.1734", "volume": "271", "author": "DR Leach", "year": "1996", "unstructured": "Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.", "journal-title": "Science"}, {"issue": "7", "key": "7_CR19", "doi-asserted-by": "publisher", "first-page": "3457", "DOI": "10.4049/jimmunol.1102316", "volume": "187", "author": "H Auchincloss", "year": "2011", "unstructured": "Auchincloss H, Turka LA. CTLA-4: not all costimulation is stimulatory. J Immunol. 2011;187(7):3457\u20138.", "journal-title": "J Immunol"}, {"key": "7_CR20", "doi-asserted-by": "publisher", "first-page": "54", "DOI": "10.3389/fonc.2018.00054", "volume": "8", "author": "T Menter", "year": "2018", "unstructured": "Menter T, Tzankov A. Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol. 2018;8:54.", "journal-title": "Front Oncol"}, {"issue": "4", "key": "7_CR21", "doi-asserted-by": "publisher", "first-page": "252", "DOI": "10.1038/nrc3239", "volume": "12", "author": "DM Pardoll", "year": "2012", "unstructured": "Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.", "journal-title": "Nat Rev Cancer"}, {"issue": "8", "key": "7_CR22", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "FS Hodi", "year": "2010", "unstructured": "Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.", "journal-title": "N Engl J Med"}, {"issue": "10", "key": "7_CR23", "doi-asserted-by": "publisher", "first-page": "1191", "DOI": "10.1200/JCO.2014.56.6018", "volume": "33", "author": "M Maio", "year": "2015", "unstructured": "Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191\u20136.", "journal-title": "J Clin Oncol"}, {"issue": "26", "key": "7_CR24", "doi-asserted-by": "publisher", "first-page": "2517", "DOI": "10.1056/NEJMe1205943", "volume": "366", "author": "A Ribas", "year": "2012", "unstructured": "Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517\u20139.", "journal-title": "N Engl J Med"}, {"issue": "26", "key": "7_CR25", "doi-asserted-by": "publisher", "first-page": "2517", "DOI": "10.1056/NEJMoa1104621", "volume": "364", "author": "C Robert", "year": "2011", "unstructured": "Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.", "journal-title": "N Engl J Med"}, {"issue": "7", "key": "7_CR26", "doi-asserted-by": "publisher", "first-page": "1581", "DOI": "10.1182/blood-2008-07-168468", "volume": "113", "author": "A Bashey", "year": "2009", "unstructured": "Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581\u20138.", "journal-title": "Blood"}, {"key": "7_CR27", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1182/blood.V126.23.585.585", "volume": "126", "author": "CS Diefenbach", "year": "2015", "unstructured": "Diefenbach CS, Hong FX, Cohen JB, Robertson MJ, Ambinder RF, Fenske TS, et al. Preliminary safety and efficacy of the combination of Brentuximab Vedotin and Ipilimumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer research group (E4412). Blood. 2015;126:23.", "journal-title": "Blood"}, {"key": "7_CR28", "doi-asserted-by": "publisher", "first-page": "250", "DOI": "10.20517/2394-4722.2017.41", "volume": "3", "author": "SJ Oiseth", "year": "2017", "unstructured": "Oiseth SJ, Aziz Mohamed S. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250\u201361.", "journal-title": "J Cancer Metastasis Treat"}, {"issue": "26", "key": "7_CR29", "doi-asserted-by": "publisher", "first-page": "2521", "DOI": "10.1056/NEJMoa1503093", "volume": "372", "author": "C Robert", "year": "2015", "unstructured": "Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.", "journal-title": "N Engl J Med"}, {"key": "7_CR30", "doi-asserted-by": "publisher", "first-page": "E24", "DOI": "10.1016/j.ejca.2015.06.072", "volume": "51", "author": "A Ribas", "year": "2015", "unstructured": "Ribas A, Wolchok JD, Robert C, Kefford R, Hamid O, Daud A, et al. Updated clinical efficacy of the anti-Pd-1 monoclonal antibody Pembrolizumab (Mk-3475) in 411 patients with Melanoma. Eur J Cancer. 2015;51:E24\u2013E.", "journal-title": "Eur J Cancer"}, {"issue": "8", "key": "7_CR31", "doi-asserted-by": "publisher", "first-page": "908", "DOI": "10.1016/S1470-2045(15)00083-2", "volume": "16", "author": "A Ribas", "year": "2015", "unstructured": "Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318.", "journal-title": "Lancet Oncol"}, {"issue": "10105", "key": "7_CR32", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.1016/S0140-6736(17)31601-X", "volume": "390", "author": "J Schachter", "year": "2017", "unstructured": "Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362.", "journal-title": "Lancet"}, {"issue": "4", "key": "7_CR33", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1038/nrclinonc.2016.168", "volume": "14", "author": "A Goodman", "year": "2017", "unstructured": "Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203\u201320.", "journal-title": "Nat Rev Clin Oncol"}, {"issue": "31", "key": "7_CR34", "doi-asserted-by": "publisher", "first-page": "3733", "DOI": "10.1200/JCO.2016.67.3467", "volume": "34", "author": "P Armand", "year": "2016", "unstructured": "Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol. 2016;34(31):3733\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "7_CR35", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1038/nri3405", "volume": "13", "author": "L Chen", "year": "2013", "unstructured": "Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.", "journal-title": "Nat Rev Immunol"}, {"issue": "4", "key": "7_CR36", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1056/NEJMoa1411087", "volume": "372", "author": "SM Ansell", "year": "2015", "unstructured": "Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.", "journal-title": "N Engl J Med"}, {"issue": "14", "key": "7_CR37", "doi-asserted-by": "publisher", "first-page": "1428", "DOI": "10.1200/JCO.2017.76.0793", "volume": "36", "author": "P Armand", "year": "2018", "unstructured": "Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428\u201339.", "journal-title": "J Clin Oncol"}, {"key": "7_CR38", "unstructured": "ClinicalTrials.gov. Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation) [cited 2018 October 7, 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT02927769 ."}, {"issue": "21", "key": "7_CR39", "doi-asserted-by": "publisher", "first-page": "2006", "DOI": "10.1056/NEJMoa1414428", "volume": "372", "author": "MA Postow", "year": "2015", "unstructured": "Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.", "journal-title": "N Engl J Med"}, {"issue": "14", "key": "7_CR40", "doi-asserted-by": "publisher", "first-page": "1345", "DOI": "10.1056/NEJMoa1709684", "volume": "377", "author": "JD Wolchok", "year": "2017", "unstructured": "Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. New Engl J Med. 2017;377(14):1345\u201356.", "journal-title": "New Engl J Med"}, {"key": "7_CR41", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1016/j.ejca.2017.08.014", "volume": "85", "author": "JM Michot", "year": "2017", "unstructured": "Michot JM, Lazarovici J, Ghez D, Danu A, Ferme C, Bigorgne A, et al. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 2017;85:67\u201377.", "journal-title": "Eur J Cancer"}, {"issue": "23", "key": "7_CR42", "doi-asserted-by": "publisher", "first-page": "2690", "DOI": "10.1200/JCO.2016.66.4482", "volume": "34", "author": "MG Roemer", "year": "2016", "unstructured": "Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690\u20137.", "journal-title": "J Clin Oncol"}, {"key": "7_CR43", "doi-asserted-by": "publisher", "first-page": "58", "DOI": "10.1016/j.ctrv.2017.01.007", "volume": "54", "author": "J Bellmunt", "year": "2017", "unstructured": "Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58\u201367.", "journal-title": "Cancer Treat Rev"}, {"issue": "10066", "key": "7_CR44", "doi-asserted-by": "publisher", "first-page": "255", "DOI": "10.1016/S0140-6736(16)32517-X", "volume": "389", "author": "A Rittmeyer", "year": "2017", "unstructured": "Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.", "journal-title": "Lancet"}, {"issue": "Suppl 13", "key": "7_CR45", "doi-asserted-by": "publisher", "first-page": "S1468", "DOI": "10.21037/jtd.2018.01.112", "volume": "10", "author": "DF Heigener", "year": "2018", "unstructured": "Heigener DF, Reck M. Advanced non-small cell lung cancer: the role of PD-L1 inhibitors. J Thorac Dis. 2018;10(Suppl 13):S1468\u2013S73.", "journal-title": "J Thorac Dis"}, {"issue": "3", "key": "7_CR46", "doi-asserted-by": "publisher", "first-page": "409", "DOI": "10.1007/s11523-018-0571-4", "volume": "13", "author": "M Shirley", "year": "2018", "unstructured": "Shirley M. Avelumab: a review in metastatic Merkel cell carcinoma. Target Oncol. 2018;13(3):409\u201316.", "journal-title": "Target Oncol"}, {"key": "7_CR47", "doi-asserted-by": "publisher", "first-page": "71", "DOI": "10.1016/j.ctrv.2016.11.007", "volume": "52", "author": "JS O\u2019Donnell", "year": "2017", "unstructured": "O\u2019Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71\u201381.", "journal-title": "Cancer Treat Rev"}, {"issue": "1", "key": "7_CR48", "doi-asserted-by": "publisher", "first-page": "111", "DOI": "10.1186/s13073-016-0365-1", "volume": "8", "author": "JS O\u2019Donnell", "year": "2016", "unstructured": "O\u2019Donnell JS, Smyth MJ, Teng MW. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med. 2016;8(1):111.", "journal-title": "Genome Med"}, {"issue": "9", "key": "7_CR49", "doi-asserted-by": "publisher", "first-page": "819", "DOI": "10.1056/NEJMoa1604958", "volume": "375", "author": "JM Zaretsky", "year": "2016", "unstructured": "Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.", "journal-title": "N Engl J Med"}, {"issue": "7528", "key": "7_CR50", "doi-asserted-by": "publisher", "first-page": "568", "DOI": "10.1038/nature13954", "volume": "515", "author": "PC Tumeh", "year": "2014", "unstructured": "Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.", "journal-title": "Nature"}, {"issue": "11", "key": "7_CR51", "doi-asserted-by": "publisher", "first-page": "2139", "DOI": "10.1158/0008-5472.CAN-15-0255", "volume": "75", "author": "MW Teng", "year": "2015", "unstructured": "Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139\u201345.", "journal-title": "Cancer Res"}, {"issue": "3", "key": "7_CR52", "doi-asserted-by": "publisher", "first-page": "285", "DOI": "10.1016/j.ccell.2016.02.004", "volume": "29", "author": "H Tang", "year": "2016", "unstructured": "Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29(3):285\u201396.", "journal-title": "Cancer Cell"}, {"issue": "6", "key": "7_CR53", "doi-asserted-by": "publisher", "first-page": "1120", "DOI": "10.1016/j.cell.2017.07.024", "volume": "170", "author": "SC Wei", "year": "2017", "unstructured": "Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120\u201333 e17.", "journal-title": "Cell"}, {"issue": "66", "key": "7_CR54", "doi-asserted-by": "publisher", "first-page": "110693", "DOI": "10.18632/oncotarget.22690", "volume": "8", "author": "J Bai", "year": "2017", "unstructured": "Bai J, Gao Z, Li X, Dong L, Han W, Nie J. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget. 2017;8(66):110693\u2013707.", "journal-title": "Oncotarget"}, {"issue": "6230", "key": "7_CR55", "doi-asserted-by": "publisher", "first-page": "69", "DOI": "10.1126/science.aaa4971", "volume": "348", "author": "TN Schumacher", "year": "2015", "unstructured": "Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.", "journal-title": "Science"}, {"issue": "1", "key": "7_CR56", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1038/bjc.2017.434", "volume": "118", "author": "RW Jenkins", "year": "2018", "unstructured": "Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9\u201316.", "journal-title": "Br J Cancer"}, {"issue": "6230", "key": "7_CR57", "doi-asserted-by": "publisher", "first-page": "124", "DOI": "10.1126/science.aaa1348", "volume": "348", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.", "journal-title": "Science"}, {"issue": "3", "key": "7_CR58", "doi-asserted-by": "publisher", "first-page": "264", "DOI": "10.1158/2159-8290.CD-16-0828", "volume": "7", "author": "V Anagnostou", "year": "2017", "unstructured": "Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer. Cancer Discov. 2017;7(3):264\u201376.", "journal-title": "Cancer Discov"}, {"issue": "4", "key": "7_CR59", "doi-asserted-by": "publisher", "first-page": "448", "DOI": "10.4103/0366-6999.176084", "volume": "129", "author": "L Li", "year": "2016", "unstructured": "Li L, Dong M, Wang XG. The implication and significance of Beta 2 microglobulin: a conservative multifunctional regulator. Chin Med J. 2016;129(4):448\u201355.", "journal-title": "Chin Med J"}, {"issue": "11", "key": "7_CR60", "doi-asserted-by": "publisher", "first-page": "910", "DOI": "10.1158/2326-6066.CIR-16-0201", "volume": "4", "author": "MG Roemer", "year": "2016", "unstructured": "Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, et al. Classical Hodgkin lymphoma with reduced beta2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res. 2016;4(11):910\u20136.", "journal-title": "Cancer Immunol Res"}, {"issue": "27", "key": "7_CR61", "doi-asserted-by": "publisher", "first-page": "11091", "DOI": "10.1073/pnas.1222251110", "volume": "110", "author": "S Loi", "year": "2013", "unstructured": "Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA. 2013;110(27):11091\u20136.", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "5", "key": "7_CR62", "doi-asserted-by": "publisher", "first-page": "506", "DOI": "10.1158/2326-6066.CIR-14-0211", "volume": "3", "author": "PA Beavis", "year": "2015", "unstructured": "Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3(5):506\u201317.", "journal-title": "Cancer Immunol Res"}, {"issue": "16", "key": "7_CR63", "doi-asserted-by": "publisher", "first-page": "1490", "DOI": "10.1056/NEJMp1510079", "volume": "373", "author": "A Ribas", "year": "2015", "unstructured": "Ribas A. Releasing the brakes on Cancer immunotherapy. N Engl J Med. 2015;373(16):1490\u20132.", "journal-title": "N Engl J Med"}, {"key": "7_CR64", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1016/j.intimp.2018.06.001", "volume": "62", "author": "Kristian M. Hargadon", "year": "2018", "unstructured": "Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.", "journal-title": "International Immunopharmacology"}, {"issue": "2", "key": "7_CR65", "doi-asserted-by": "publisher", "first-page": "158", "DOI": "10.1056/NEJMra1703481", "volume": "378", "author": "Michael A. Postow", "year": "2018", "unstructured": "Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.", "journal-title": "New England Journal of Medicine"}], "container-title": ["Resistance to Targeted Anti-Cancer Therapeutics", "Resistance to Targeted Therapies in Lymphomas"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-030-24424-8_7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 12, 7]], "date-time": "2019-12-07T05:57:37Z", "timestamp": 1575698257000}, "score": 19.366968, "issued": {"date-parts": [[2019]]}, "ISBN": ["9783030244231", "9783030244248"], "references-count": 65, "URL": "http://dx.doi.org/10.1007/978-3-030-24424-8_7", "relation": {"cites": []}, "ISSN": ["2196-5501", "2196-551X"], "issn-type": [{"value": "2196-5501", "type": "print"}, {"value": "2196-551X", "type": "electronic"}], "assertion": [{"value": "14 September 2019", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ChapterHistory", "label": "Chapter History"}}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T11:07:32Z", "timestamp": 1574593652879}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "16", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2015, 8, 15]]}, "DOI": "10.1158/1078-0432.ccr-15-0407", "type": "journal-article", "created": {"date-parts": [[2015, 4, 7]], "date-time": "2015-04-07T01:23:22Z", "timestamp": 1428369802000}, "page": "3584-3585", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Next-Generation Sequencing: Targeting Targeted Therapies"], "prefix": "10.1158", "volume": "21", "author": [{"given": "J. N.", "family": "McCutcheon", "sequence": "first", "affiliation": []}, {"given": "G.", "family": "Giaccone", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2015, 4, 6]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-15-0407", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T04:29:54Z", "timestamp": 1482467394000}, "score": 19.235071, "issued": {"date-parts": [[2015, 4, 6]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2015, 8, 13]]}, "published-print": {"date-parts": [[2015, 8, 15]]}, "issue": "16"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-15-0407", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T01:08:28Z", "timestamp": 1574730508812}, "reference-count": 190, "publisher": "IGI Global", "isbn-type": [{"value": "9781522517627", "type": "print"}, {"value": "9781522517634", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2017]]}, "abstract": "<jats:p>Advancements in cancer drug delivery have led to the development of personalized oncology care through molecularly-driven targeted therapies. Understanding molecular and cellular mechanisms which drive tumor progression and resistance is critical in managing new treatment strategies which have shifted from empiric to biomarker-directed therapy selection. Biomarker-directed therapies have improved clinical outcomes in multiple malignancies as monotherapy and in combination with other treatment modalities, however the changing scope of treatment options presents new opportunities and challenges for research. Furthermore, pharmacogenetics may provide a rationale method of personalizing anticancer drug dosing and supportive care management for oncology patients. This chapter reviews biomarker classifications and pharmacogenetics in anticancer therapy and supportive care. Examples of biomarker-directed therapies and clinical assays, in addition to future directions of molecular profiling in oncology therapy management are discussed.</jats:p>", "DOI": "10.4018/978-1-5225-1762-7.ch008", "type": "book-chapter", "created": {"date-parts": [[2016, 12, 28]], "date-time": "2016-12-28T15:51:45Z", "timestamp": 1482940305000}, "page": "185-228", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Cancer Drug Delivery"], "prefix": "10.4018", "author": [{"given": "Jai N.", "family": "Patel", "sequence": "first", "affiliation": [{"name": "Levine Cancer Institute, USA"}]}, {"given": "Jeryl", "family": "Villadolid", "sequence": "additional", "affiliation": [{"name": "Levine Cancer Institute, USA"}]}], "member": "2432", "reference": [{"key": "978-1-5225-1762-7.ch008.-1", "DOI": "10.1007/s10549-009-0704-7", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-2", "DOI": "10.1200/JCO.2007.14.7116", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-3", "DOI": "10.1038/nrclinonc.2011.177", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-4", "DOI": "10.1016/j.clpt.2005.08.015", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-5", "DOI": "10.1038/nm.2438", "doi-asserted-by": "publisher"}, {"issue": "31", "key": "978-1-5225-1762-7.ch008.-6", "doi-asserted-by": "crossref", "first-page": "4189", "DOI": "10.1200/JCO.2010.34.4614", "article-title": "Antiemetics: American Society of Clinical Oncology clinical practice guideline update.", "volume": "29", "author": "E.Basch", "year": "2011", "journal-title": "Journal of Clinical Oncology"}, {"key": "978-1-5225-1762-7.ch008.-7", "DOI": "10.1056/NEJMoa1113216", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-8", "DOI": "10.1073/pnas.0710370104", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-9", "DOI": "10.1016/S1470-2045(12)70477-1", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-10", "DOI": "10.1634/theoncologist.11-2-126", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-11", "DOI": "10.1046/j.0306-5251.2001.01548.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-12", "author": "D.Bixby", "year": "2009", "journal-title": "Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance"}, {"key": "978-1-5225-1762-7.ch008.-13", "DOI": "10.1111/j.1365-2125.1994.tb04397.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-14", "DOI": "10.1097/00130404-200209000-00012", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-15", "DOI": "10.1517/14622416.3.2.229", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-16", "DOI": "10.1200/JCO.2012.44.6625", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-17", "DOI": "10.1007/s002100000342", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-18", "DOI": "10.1038/clpt.2013.172", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-19", "DOI": "10.1056/NEJMoa1103782", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-20", "DOI": "10.1111/j.1399-6576.2006.01058.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-21", "DOI": "10.1056/NEJMc0904266", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-22", "unstructured": "Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., . . . Skaar, T. C. (2014). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clinical Pharmacology and Therapeutics.", "DOI": "10.1038/clpt.2013.254", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-23", "DOI": "10.1038/300765a0", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-24", "DOI": "10.1007/s00280-005-1033-0", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-25", "DOI": "10.1634/theoncologist.2010-0258", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-26", "unstructured": "Deenen, M. J., Cats, A., Sechterberger, M. K., Severens, J. L., Smits, P. H. M., Bakker, R., . . . Schellens, J. H. M. (2011). Safety, pharmacokinetics (PK), and cost effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. Journal of Clinical Oncology, 29.", "DOI": "10.1200/jco.2011.29.15_suppl.3606", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-27", "unstructured": "Demetri, G. D., Rankin, C.J., Benjamin, R. S., Boreden, E.C., Ryan, C.W., Priebat, D.A., . . . Blanke, C.D. (2014). Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. Journal of Clinical Oncology, 32(5).", "DOI": "10.1200/jco.2014.32.15_suppl.10508", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-28", "DOI": "10.1016/S0140-6736(12)61857-1", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-29", "DOI": "10.1016/S0140-6736(06)69446-4", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-30", "DOI": "10.1200/JCO.2008.18.0786", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-31", "DOI": "10.1056/NEJMoa1305275", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-32", "unstructured": "Duad, A., Ribas, A., & Robert, C. (2015). Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. Journal of Clinical Oncology.", "DOI": "10.1200/jco.2015.33.15_suppl.9005", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-33", "DOI": "10.1158/1078-0432.CCR-09-0095", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-34", "DOI": "10.1016/S1542-3565(04)00243-5", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-35", "DOI": "10.1007/s00432-008-0387-1", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-36", "DOI": "10.1016/S0193-953X(02)00107-7", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-37", "DOI": "10.1038/nm0603-669", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-38", "DOI": "10.1093/annonc/mdq600", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-39", "DOI": "10.1182/asheducation-2011.1.231", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-40", "DOI": "10.1056/NEJMoa1210093", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-41", "DOI": "10.1016/S0140-6736(13)61719-5", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-42", "DOI": "10.1007/s005200050160", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-43", "DOI": "10.1016/S0140-6736(14)60845-X", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-44", "DOI": "10.1056/NEJMoa041888", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-45", "DOI": "10.1097/PPO.0b013e318212db3c", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-46", "DOI": "10.1056/NEJMoa1113205", "doi-asserted-by": "publisher"}, {"issue": "26", "key": "978-1-5225-1762-7.ch008.-47", "doi-asserted-by": "crossref", "first-page": "2733", "DOI": "10.1056/NEJMoa064320", "article-title": "Lapatinib plus capecitabine for HER2-positive advanced breast cancer.", "volume": "355", "author": "C. E.Geyer", "year": "2006", "journal-title": "The New England Journal of Medicine"}, {"issue": "2", "key": "978-1-5225-1762-7.ch008.-48", "doi-asserted-by": "crossref", "DOI": "10.1093/jnci/dju401", "article-title": "Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for germline pharmacogenetic studies.", "volume": "107", "author": "M. P.Goetz", "year": "2015", "journal-title": "Journal of the National Cancer Institute"}, {"key": "978-1-5225-1762-7.ch008.-49", "DOI": "10.1126/science.1062538", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-50", "DOI": "10.1007/s00228-004-0766-8", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-51", "DOI": "10.1007/s10156-011-0363-6", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-52", "DOI": "10.1097/FTD.0b013e31820530cd", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-53", "DOI": "10.1016/S0140-6736(12)60868-X", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-54", "unstructured": "He, H., Yin, J. Y., Xu, Y. J., Li, X., Zhang, Y., Liu, Z. G., . . . Liu, Z. Q. (2014). Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clinical Therapeutics, 36(8), 1242-1252.", "DOI": "10.1016/j.clinthera.2014.06.016", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-55", "DOI": "10.1200/JCO.2003.04.190", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-56", "DOI": "10.1038/315758a0", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-57", "DOI": "10.1016/S0140-6736(11)60545-X", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-58", "DOI": "10.1111/j.1469-0691.2012.03772.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-59", "DOI": "10.2217/pgs.14.53", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-60", "DOI": "10.1038/clpt.2013.2", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-61", "DOI": "10.1073/pnas.172398299", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-62", "DOI": "10.1093/jnci/djm115", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-63", "DOI": "10.1177/0269881111414451", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-64", "DOI": "10.1200/JCO.2012.44.9694", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-65", "DOI": "10.1634/theoncologist.2013-0107", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-66", "DOI": "10.1016/j.tips.2004.02.007", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-67", "DOI": "10.1200/JCO.2014.55.2307", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "978-1-5225-1762-7.ch008.-68", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1186/s13045-015-0122-8", "article-title": "Novel ALK inhibitors in clinical use and development.", "volume": "8", "author": "C.Iragavarapu", "year": "2015", "journal-title": "Journal of Hematology and Oncology"}, {"key": "978-1-5225-1762-7.ch008.-69", "DOI": "10.1200/JCO.2010.31.4427", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-70", "DOI": "10.2133/dmpk.19.1", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-71", "DOI": "10.1182/blood-2011-04-348110", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-72", "DOI": "10.1155/2010/150960", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-73", "DOI": "10.1093/jnci/dji005", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-74", "DOI": "10.1177/0091270009337946", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-75", "DOI": "10.1200/JCO.2002.09.064", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-76", "DOI": "10.1111/j.1399-6576.2004.00517.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-77", "DOI": "10.1016/S0140-6736(06)69255-6", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-78", "DOI": "10.1097/FPC.0b013e3280117269", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-79", "DOI": "10.1093/jnci/djt072", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-80", "DOI": "10.1200/JCO.2007.12.5906", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-81", "DOI": "10.4088/JCP.08m04773blu", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-82", "DOI": "10.1021/bi00013a008", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-83", "DOI": "10.1056/NEJMoa040938", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-84", "DOI": "10.1158/2159-8290.CD-11-0110", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-85", "DOI": "10.1016/j.pharmthera.2011.02.003", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-86", "DOI": "10.2174/157488611794479991", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-87", "DOI": "10.1038/clpt.2010.125", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-88", "DOI": "10.2217/14622416.9.9.1267", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-89", "DOI": "10.1038/clpt.2011.32", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-90", "DOI": "10.1200/JCO.2009.22.3701", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-91", "DOI": "10.1038/bjc.2011.206", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-92", "DOI": "10.1158/1078-0432.CCR-06-3043", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-93", "unstructured": "Mauro, M. J. (2006). Defining and managing imatinib resistance. Hematology American Society of Hematology Education Program.", "DOI": "10.1182/asheducation-2006.1.219", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-94", "DOI": "10.1016/S1470-2045(14)70012-9", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-95", "DOI": "10.1038/sj.leu.2401723", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-96", "DOI": "10.1038/clpt.1994.4", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-97", "DOI": "10.1016/0024-3205(95)00010-4", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-98", "DOI": "10.2217/pgs.11.18", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-99", "DOI": "10.1016/S1470-2045(12)70087-6", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-100", "DOI": "10.1111/j.1469-0691.2009.02990.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-101", "first-page": "CD006243", "article-title": "Trastuzumab containing regimens for early breast cancer.", "volume": "4", "author": "L.Moja", "year": "2012", "journal-title": "Cochrane Database of Systematic Reviews"}, {"key": "978-1-5225-1762-7.ch008.-102", "DOI": "10.1093/jat/30.7.463", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-103", "DOI": "10.1093/jnci/djs304", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-104", "DOI": "10.2217/pgs.12.1", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-105", "DOI": "10.2165/11586630-000000000-00000", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-106", "DOI": "10.1007/s00228-009-0657-0", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-107", "DOI": "10.1002/phar.1400", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-108", "DOI": "10.1038/nrc3239", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-109", "DOI": "10.1093/cid/cis599", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-110", "DOI": "10.2217/pgs.13.227", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-111", "DOI": "10.2217/pgs.13.88", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-112", "DOI": "10.1177/1078155212473862", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-113", "DOI": "10.1592/phco.28.6.755", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-114", "DOI": "10.1200/JCO.2012.47.6143", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-115", "DOI": "10.1093/jac/dks258", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-116", "unstructured": "Planchard, D., Mazieres, J., Riely, G. J., Rudin, C. M., Barlesi, F., Quoix, E. A., & Souquet, M. A. (2013). Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation\u2013positive non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology."}, {"key": "978-1-5225-1762-7.ch008.-117", "DOI": "10.1056/NEJMoa1414428", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-118", "DOI": "10.1038/nature10868", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-119", "DOI": "10.1093/jnci/djs126", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-120", "DOI": "10.1093/jnci/djt204", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-121", "DOI": "10.1016/j.pain.2005.03.032", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-122", "DOI": "10.1093/jnci/djs125", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-123", "DOI": "10.1093/annonc/mdr598", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-124", "DOI": "10.1038/clpt.2010.320", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-125", "DOI": "10.1038/clpt.2013.4", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-126", "DOI": "10.1093/jnci/91.23.2001", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-127", "DOI": "10.1016/S1470-2045(15)70054-9", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-128", "DOI": "10.1056/NEJMoa1412690", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-129", "DOI": "10.1056/NEJMoa1412082", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-130", "DOI": "10.1056/NEJMoa1503093", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-131", "DOI": "10.1093/annonc/mdq194", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-132", "DOI": "10.1016/j.ejphar.2012.01.046", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-133", "DOI": "10.1016/S1470-2045(11)70393-X", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-134", "DOI": "10.1200/JCO.2013.51.1857", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-135", "DOI": "10.1177/106689690000800105", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "978-1-5225-1762-7.ch008.-136", "doi-asserted-by": "crossref", "first-page": "1905", "DOI": "10.1176/ajp.2006.163.11.1905", "article-title": "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report.", "volume": "163", "author": "A. J.Rush", "year": "2006", "journal-title": "The American Journal of Psychiatry"}, {"key": "978-1-5225-1762-7.ch008.-137", "DOI": "10.1007/s00280-006-0392-5", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-138", "author": "P.Saladores", "year": "2014", "article-title": "Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.", "journal-title": "The Pharmacogenomics Journal"}, {"key": "978-1-5225-1762-7.ch008.-139", "DOI": "10.1111/j.1476-5381.2010.00709.x", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-140", "DOI": "10.1007/s40291-013-0028-5", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-141", "DOI": "10.1038/nature06913", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-142", "DOI": "10.1097/01.fpc.0000114745.08559.db", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-143", "DOI": "10.1158/1078-0432.CCR-08-2576", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-144", "DOI": "10.1001/jama.2009.1420", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-145", "DOI": "10.1200/JCO.2006.10.4182", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-146", "DOI": "10.1056/NEJMoa1413654", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-147", "DOI": "10.1097/YIC.0b013e32832e5b0d", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-148", "DOI": "10.1016/S1470-2045(13)70142-6", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-149", "DOI": "10.1056/NEJMoa1311107", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-150", "DOI": "10.1056/NEJMoa1214886", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-151", "DOI": "10.1056/NEJMoa050753", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-152", "DOI": "10.1056/NEJMoa1408440", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-153", "unstructured": "Spigel, D.R., Reckamp, K.L., Rizvi, N.A., Poddubskaya, E., West, H.J, Eberhardt, W.E.E, . . . Brahmer, J.R. (2015). A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) versus docetaxel (DOC) in previously treated advanced or metastatic squamous cell non-small cell lung cancer. Journal of Clinical Oncology.", "DOI": "10.1200/jco.2015.33.15_suppl.8009", "doi-asserted-by": "crossref"}, {"key": "978-1-5225-1762-7.ch008.-154", "DOI": "10.1007/s00213-002-1084-4", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-155", "DOI": "10.1016/S0304-3959(03)00212-4", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-156", "DOI": "10.1038/sj.clpt.6100152", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-157", "DOI": "10.1213/ane.0b013e31817b796e", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-158", "DOI": "10.1371/journal.pone.0060239", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-159", "DOI": "10.1001/jama.293.12.1485", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-160", "DOI": "10.1016/j.cca.2013.11.015", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-161", "DOI": "10.1038/clpt.2008.154", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-162", "DOI": "10.1056/NEJMoa1105358", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-163", "DOI": "10.1016/S1470-2045(15)70127-0", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-164", "DOI": "10.1200/JCO.2010.32.3212", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-165", "DOI": "10.1016/S0140-6736(05)67625-8", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-166", "DOI": "10.2217/14622416.8.5.497", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-167", "DOI": "10.1200/JCO.2009.23.6125", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-168", "DOI": "10.1200/JCO.2011.39.2316", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-169", "DOI": "10.1200/JCO.2003.05.164", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-170", "DOI": "10.1002/cncr.22568", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-171", "DOI": "10.1177/1060028013513009", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-172", "DOI": "10.1128/AAC.01083-10", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-173", "DOI": "10.1038/tpj.2010.75", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-174", "DOI": "10.1056/NEJMoa0805019", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-175", "DOI": "10.1200/JCO.2012.42.8201", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-176", "DOI": "10.1097/00008571-200210000-00007", "doi-asserted-by": "publisher"}, {"issue": "6", "key": "978-1-5225-1762-7.ch008.-177", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1200/JCO.2001.19.6.1779", "article-title": "Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.", "volume": "19", "author": "E.Villafranca", "year": "2001", "journal-title": "Journal of Clinical Oncology"}, {"key": "978-1-5225-1762-7.ch008.-178", "DOI": "10.1016/j.ijantimicag.2014.07.013", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-179", "DOI": "10.2217/14622416.9.8.1027", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-180", "DOI": "10.1016/S1470-2045(15)70076-8", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-181", "DOI": "10.1016/S1470-2045(14)70420-6", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-182", "DOI": "10.2174/156652411794474392", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-183", "DOI": "10.1016/S1470-2045(14)71173-8", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-184", "DOI": "10.1016/j.cell.2007.11.013", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-185", "DOI": "10.1007/s10620-007-9759-7", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-186", "DOI": "10.1016/j.ejca.2007.01.030", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-187", "DOI": "10.2174/138161212800672732", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-188", "DOI": "10.2174/156802611795860924", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-189", "DOI": "10.1016/S1470-2045(11)70184-X", "doi-asserted-by": "publisher"}, {"key": "978-1-5225-1762-7.ch008.-190", "DOI": "10.1111/j.1747-0285.2010.01054.x", "doi-asserted-by": "publisher"}], "container-title": ["Pharmaceutical Sciences"], "link": [{"URL": "https://www.igi-global.com/viewtitle.aspx?TitleId=174126", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 17]], "date-time": "2019-09-17T01:19:21Z", "timestamp": 1568683161000}, "score": 19.235071, "subtitle": ["Pharmacogenetics, Biomarkers, and Targeted Therapies"], "issued": {"date-parts": [[2017]]}, "ISBN": ["9781522517627", "9781522517634"], "references-count": 190, "URL": "http://dx.doi.org/10.4018/978-1-5225-1762-7.ch008", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T12:12:36Z", "timestamp": 1575202356706}, "publisher-location": "Unitec House, 2 Albert Place, London N3 1QB, UK", "reference-count": 23, "publisher": "Future Medicine Ltd", "isbn-type": [{"value": "9781780840109", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 11]]}, "DOI": "10.2217/ebo.11.66", "type": "other", "created": {"date-parts": [[2013, 3, 26]], "date-time": "2013-03-26T16:30:06Z", "timestamp": 1364315406000}, "page": "80-90", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Chemotherapy for castration-resistant prostate cancer"], "prefix": "10.2217", "author": [{"given": "Guru", "family": "Sonpavde", "sequence": "first", "affiliation": []}, {"given": "Cora N", "family": "Sternberg", "sequence": "additional", "affiliation": []}], "member": "1057", "published-online": {"date-parts": [[2011, 11, 17]]}, "reference": [{"issue": "6", "key": "ch7-bid.1", "doi-asserted-by": "crossref", "first-page": "1756", "DOI": "10.1200/JCO.1996.14.6.1756", "volume": "14", "author": "Tannock IF", "year": "1996", "journal-title": "J. Clin. Oncol."}, {"key": "ch7-bid.2", "DOI": "10.1200/JCO.2007.12.4008", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.3", "DOI": "10.1056/NEJMoa041318", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.4", "author": "Armstrong AJ", "volume": "46", "issue": "3", "first-page": "517", "journal-title": "Eur. J. Cancer", "DOI": "10.1016/j.ejca.2009.11.007", "doi-asserted-by": "crossref"}, {"key": "ch7-bid.5", "DOI": "10.1200/JCO.2007.12.4487", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.6", "DOI": "10.1158/1078-0432.CCR-07-1036", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.7", "DOI": "10.1200/JCO.2003.06.100", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.8", "DOI": "10.1093/jnci/djj129", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.9", "DOI": "10.1200/JCO.2007.11.4769", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.10", "DOI": "10.1200/JCO.2008.19.9810", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "ch7-bid.11", "doi-asserted-by": "crossref", "first-page": "203", "DOI": "10.1158/1078-0432.CCR-09-2514", "volume": "16", "author": "Armstrong AJ", "year": "2009", "journal-title": "Clin. Cancer Res."}, {"key": "ch7-bid.12", "DOI": "10.1200/JCO.2008.18.9159", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.13", "DOI": "10.1002/cncr.25982", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.14", "author": "Armstrong AJ", "volume": "16", "issue": "1", "first-page": "203", "journal-title": "Clin. Cancer Res.", "DOI": "10.1158/1078-0432.CCR-09-2514", "doi-asserted-by": "crossref"}, {"key": "ch7-bid.15", "DOI": "10.1158/1078-0432.CCR-08-0872", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.16", "DOI": "10.1093/annonc/mdn288", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.17", "DOI": "10.1002/cncr.23163", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.18", "author": "Kelly WK", "volume": "28", "issue": "18", "year": "2010", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2012.41.8889", "doi-asserted-by": "crossref"}, {"key": "ch7-bid.19", "DOI": "10.1016/S0140-6736(10)61389-X", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.20", "DOI": "10.1200/JCO.2008.20.1228", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "ch7-bid.21", "first-page": "521", "volume": "112", "author": "Ross RW", "year": "2008", "journal-title": "docetaxel"}, {"key": "ch7-bid.22", "DOI": "10.1002/cncr.22811", "doi-asserted-by": "publisher"}, {"key": "ch7-bid.23", "author": "de Bono JS", "year": "2011", "journal-title": "Ann. Oncol."}], "container-title": ["Targeted Therapies for Castration-Resistant Prostate Cancer"], "link": [{"URL": "https://www.futuremedicine.com/doi/pdf/10.2217/ebo.11.66", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T10:28:19Z", "timestamp": 1574245699000}, "score": 19.235071, "issued": {"date-parts": [[2011, 11]]}, "ISBN": ["9781780840109"], "references-count": 23, "alternative-id": ["10.2217/ebo.11.66", "10.2217/9781780840109"], "URL": "http://dx.doi.org/10.2217/ebo.11.66", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T17:36:11Z", "timestamp": 1574271371334}, "reference-count": 66, "publisher": "Wiley", "issue": "10", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3129, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Int. J. Cancer"], "published-print": {"date-parts": [[2007, 5, 15]]}, "DOI": "10.1002/ijc.22138", "type": "journal-article", "created": {"date-parts": [[2007, 2, 6]], "date-time": "2007-02-06T18:49:37Z", "timestamp": 1170787777000}, "page": "2233-2242", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Towards a ligand targeted enzyme prodrug therapy: Single round panning of a \u03b2-lactamase scaffold library on human cancer cells"], "prefix": "10.1002", "volume": "120", "author": [{"given": "Girja S.", "family": "Shukla", "sequence": "first", "affiliation": []}, {"given": "Christopher J.", "family": "Murray", "sequence": "additional", "affiliation": []}, {"given": "Melodie", "family": "Estabrook", "sequence": "additional", "affiliation": []}, {"given": "Guang-Ping", "family": "Shen", "sequence": "additional", "affiliation": []}, {"given": "Volker", "family": "Schellenberger", "sequence": "additional", "affiliation": []}, {"given": "David N.", "family": "Krag", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2007, 2, 6]]}, "reference": [{"key": "10.1002/ijc.22138-BIB1|cit2", "doi-asserted-by": "crossref", "first-page": "815", "DOI": "10.1002/1097-0142(19900201)65:3+<815::AID-CNCR2820651329>3.0.CO;2-F", "article-title": "Mechanisms to improve chemotherapy effectiveness", "volume": "65", "author": "Young", "year": "1990", "journal-title": "Cancer"}, {"key": "10.1002/ijc.22138-BIB2|cit3", "first-page": "55", "article-title": "Cancer: new therapies and new approaches to recurring problems", "volume": "71", "author": "Kirsner", "year": "2003", "journal-title": "AANA J"}, {"key": "10.1002/ijc.22138-BIB3|cit4", "doi-asserted-by": "crossref", "first-page": "750", "DOI": "10.1038/nrc903", "article-title": "Ligand-targeted therapeutics in anticancer therapy", "volume": "2", "author": "Allen", "year": "2002", "journal-title": "Nat Rev Cancer"}, {"issue": "Suppl 1", "key": "10.1002/ijc.22138-BIB4|cit5", "doi-asserted-by": "crossref", "first-page": "S11", "DOI": "10.1023/A:1024373306493", "article-title": "Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy", "volume": "79", "author": "Crown", "year": "2003", "journal-title": "Breast Cancer Res Treat"}, {"key": "10.1002/ijc.22138-BIB5|cit6", "doi-asserted-by": "crossref", "first-page": "1776", "DOI": "10.1200/JCO.2005.11.029", "article-title": "Targeted therapy: wave of the future", "volume": "23", "author": "Pegram", "year": "2005", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ijc.22138-BIB6|cit7", "doi-asserted-by": "crossref", "first-page": "436", "DOI": "10.1038/nrc1627", "article-title": "Tumour vascular targeting", "volume": "5", "author": "Neri", "year": "2005", "journal-title": "Nat Rev Cancer"}, {"key": "10.1002/ijc.22138-BIB7|cit8", "doi-asserted-by": "crossref", "first-page": "283", "DOI": "10.2165/00063030-200216040-00004", "article-title": "Monoclonal antibody therapy of haematological malignancies", "volume": "16", "author": "Dearden", "year": "2002", "journal-title": "BioDrugs"}, {"key": "10.1002/ijc.22138-BIB8|cit9", "first-page": "693", "article-title": "Targeted therapy of cancer with radiolabeled antibodies", "volume": "43", "author": "Goldenberg", "year": "2002", "journal-title": "J Nucl Med"}, {"key": "10.1002/ijc.22138-BIB9|cit10", "first-page": "177", "article-title": "Effective tumor targeting: strategies for the delivery of armed antibodies", "volume": "8", "author": "MacDonald", "year": "2005", "journal-title": "Curr Opin Drug Discov Devel"}, {"key": "10.1002/ijc.22138-BIB10|cit11", "doi-asserted-by": "crossref", "first-page": "184", "DOI": "10.1002/bip.10257", "article-title": "Therapeutic cancer targeting peptides", "volume": "66", "author": "Aina", "year": "2002", "journal-title": "Biopolymers"}, {"key": "10.1002/ijc.22138-BIB11|cit12", "doi-asserted-by": "crossref", "first-page": "604", "DOI": "10.1081/CNV-200027148", "article-title": "Tumor-activated prodrugs-a new approach to cancer therapy", "volume": "22", "author": "Denny", "year": "2004", "journal-title": "Cancer Invest"}, {"key": "10.1002/ijc.22138-BIB12|cit13", "doi-asserted-by": "crossref", "first-page": "247", "DOI": "10.1016/S0169-409X(01)00206-X", "article-title": "Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates", "volume": "53", "author": "Senter", "year": "2001", "journal-title": "Adv Drug Deliv Rev"}, {"key": "10.1002/ijc.22138-BIB13|cit14", "doi-asserted-by": "crossref", "first-page": "53", "DOI": "10.1124/pr.56.1.3", "article-title": "Enzyme-catalyzed activation of anticancer prodrugs", "volume": "56", "author": "Rooseboom", "year": "2004", "journal-title": "Pharmacol Rev"}, {"key": "10.1002/ijc.22138-BIB14|cit15", "doi-asserted-by": "crossref", "first-page": "2113", "DOI": "10.2174/1381612033454063", "article-title": "Enzyme/abzyme prodrug activation systems: potential use in clinical oncology", "volume": "9", "author": "Nishi", "year": "2003", "journal-title": "Curr Pharm Design"}, {"key": "10.1002/ijc.22138-BIB15|cit16", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.1016/S0022-1759(02)00241-7", "article-title": "Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy", "volume": "269", "author": "Kakinuma", "year": "2002", "journal-title": "J Immunol Methods"}, {"key": "10.1002/ijc.22138-BIB16|cit17", "doi-asserted-by": "crossref", "first-page": "1083", "DOI": "10.1089/hum.1998.9.7-1083", "article-title": "Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma", "volume": "9", "author": "Sterman", "year": "1998", "journal-title": "Hum Gene Ther"}, {"key": "10.1002/ijc.22138-BIB17|cit18", "doi-asserted-by": "crossref", "first-page": "1747", "DOI": "10.1016/S0022-5347(05)67534-9", "article-title": "Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer", "volume": "163", "author": "Shalev", "year": "2000", "journal-title": "J Urol"}, {"key": "10.1002/ijc.22138-BIB18|cit19", "doi-asserted-by": "crossref", "first-page": "2325", "DOI": "10.1089/10430349950016979", "article-title": "A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group", "volume": "10", "author": "Shand", "year": "1999", "journal-title": "Hum Gene Ther"}, {"key": "10.1002/ijc.22138-BIB19|cit20", "doi-asserted-by": "crossref", "first-page": "1239", "DOI": "10.1089/10430349950018229", "article-title": "In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial", "volume": "10", "author": "Herman", "year": "1999", "journal-title": "Hum Gene Ther"}, {"key": "10.1002/ijc.22138-BIB20|cit21", "doi-asserted-by": "crossref", "first-page": "1853", "DOI": "10.1038/sj.gt.3301311", "article-title": "Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme", "volume": "7", "author": "Rainov", "year": "2000", "journal-title": "Gene Ther"}, {"key": "10.1002/ijc.22138-BIB21|cit22", "doi-asserted-by": "crossref", "first-page": "225", "DOI": "10.1089/152581600319441", "article-title": "Development of a competitive PCR method for in vitro and in vivo quantification of herpes simplex virus thymidine kinase and neomycin resistance-expressing cells used in a clinical trial", "volume": "9", "author": "Maddens", "year": "2000", "journal-title": "J Hematother Stem Cell Res"}, {"key": "10.1002/ijc.22138-BIB22|cit23", "doi-asserted-by": "crossref", "first-page": "2243", "DOI": "10.1089/hum.1998.9.15-2243", "article-title": "Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors", "volume": "9", "author": "Verzeletti", "year": "1998", "journal-title": "Hum Gene Ther"}, {"key": "10.1002/ijc.22138-BIB23|cit24", "doi-asserted-by": "crossref", "first-page": "2180", "DOI": "10.1200/JCO.1999.17.7.2180", "article-title": "Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression", "volume": "17", "author": "Pandha", "year": "1999", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ijc.22138-BIB24|cit25", "first-page": "765", "article-title": "Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma", "volume": "6", "author": "Napier", "year": "2000", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/ijc.22138-BIB25|cit26", "doi-asserted-by": "crossref", "first-page": "189", "DOI": "10.1007/s002800050646", "article-title": "Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial", "volume": "40", "author": "Martin", "year": "1997", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "10.1002/ijc.22138-BIB26|cit27", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.1007/BF02789482", "article-title": "Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial", "volume": "21", "author": "Sharma", "year": "1992", "journal-title": "Cell Biophys"}, {"key": "10.1002/ijc.22138-BIB27|cit28", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/S0167-4781(02)00249-X", "article-title": "Targeted adenoviral vectors", "volume": "1575", "author": "Barnett", "year": "2002", "journal-title": "Biochim Biophys Acta"}, {"key": "10.1002/ijc.22138-BIB28|cit29", "doi-asserted-by": "crossref", "first-page": "1036", "DOI": "10.1038/sj.cgt.7700541", "article-title": "Adenoviral vectors: systemic delivery and tumor targeting", "volume": "9", "author": "Green", "year": "2002", "journal-title": "Cancer Gene Ther"}, {"key": "10.1002/ijc.22138-BIB29|cit30", "doi-asserted-by": "crossref", "first-page": "263", "DOI": "10.1615/CritRevTherDrugCarrierSyst.v12.i4.10", "article-title": "Gene introduction into animal tissues", "volume": "12", "author": "Nakanishi", "year": "1995", "journal-title": "Crit Rev Ther Drug Carrier Syst"}, {"key": "10.1002/ijc.22138-BIB30|cit31", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1111/j.2042-7158.1998.tb06878.x", "article-title": "The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies", "volume": "50", "author": "Denny", "year": "1998", "journal-title": "J Pharm Pharmacol"}, {"key": "10.1002/ijc.22138-BIB31|cit32", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1042/bj1870001", "article-title": "The kinetics of antibody binding to membrane antigens in solution and at the cell surface", "volume": "187", "author": "Mason", "year": "1980", "journal-title": "Biochem J"}, {"key": "10.1002/ijc.22138-BIB32|cit33", "doi-asserted-by": "crossref", "first-page": "811", "DOI": "10.1038/sj.bjc.6600143", "article-title": "A fully human anti-Ep-CAM scFv-\u03b2-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug", "volume": "86", "author": "de Graaf", "year": "2002", "journal-title": "Br J Cancer"}, {"key": "10.1002/ijc.22138-BIB33|cit34", "doi-asserted-by": "crossref", "first-page": "571", "DOI": "10.1002/(SICI)1097-0215(20000215)85:4<571::AID-IJC20>3.0.CO;2-1", "article-title": "Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein", "volume": "85", "author": "Bhatia", "year": "2000", "journal-title": "Int J Cancer"}, {"key": "10.1002/ijc.22138-BIB34|cit35", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1016/1380-2933(96)00033-4", "article-title": "In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein", "volume": "2", "author": "Michael", "year": "1996", "journal-title": "Immunotechnology"}, {"key": "10.1002/ijc.22138-BIB35|cit36", "first-page": "184", "article-title": "Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human \u03b2-glucuronidase for antibody-directed enzyme prodrug therapy", "volume": "92", "author": "Haisma", "year": "1998", "journal-title": "Blood"}, {"key": "10.1002/ijc.22138-BIB36|cit37", "first-page": "313", "article-title": "PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites", "volume": "29", "author": "Wong", "year": "2001", "journal-title": "Drug Metab Dispos"}, {"key": "10.1002/ijc.22138-BIB37|cit38", "first-page": "63", "article-title": "Development of a humanized disulfide-stabilized anti-p185HER2 Fv-\u03b2-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug", "volume": "55", "author": "Rodrigues", "year": "1995", "journal-title": "Cancer Res"}, {"key": "10.1002/ijc.22138-BIB38|cit39", "doi-asserted-by": "crossref", "first-page": "2853", "DOI": "10.1158/0008-5472.CAN-03-3935", "article-title": "Efficient cancer therapy with a nanobody-based conjugate", "volume": "64", "author": "Cortez-Retamozo", "year": "2004", "journal-title": "Cancer Res"}, {"key": "10.1002/ijc.22138-BIB39|cit40", "doi-asserted-by": "crossref", "first-page": "6762", "DOI": "10.1021/bi00188a004", "article-title": "Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a \u03b2-lactamase transition-state analog", "volume": "33", "author": "Lobkovsky", "year": "1994", "journal-title": "Biochemistry"}, {"key": "10.1002/ijc.22138-BIB40|cit41", "doi-asserted-by": "crossref", "first-page": "367", "DOI": "10.1016/0076-6879(87)54085-X", "article-title": "Rapid and efficient site-specific mutagenesis without phenotypic selection", "volume": "154", "author": "Kunkel", "year": "1987", "journal-title": "Methods Enzymol"}, {"key": "10.1002/ijc.22138-BIB41|cit42", "doi-asserted-by": "crossref", "first-page": "75", "DOI": "10.1038/83567", "article-title": "A helper phage to improve single-chain antibody presentation in phage display", "volume": "19", "author": "Rondot", "year": "2001", "journal-title": "Nat Biotechnol"}, {"key": "10.1002/ijc.22138-BIB42|cit43", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1080/10611860400020464", "article-title": "Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens", "volume": "13", "author": "Shukla", "year": "2005", "journal-title": "J Drug Target"}, {"key": "10.1002/ijc.22138-BIB43|cit44", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1007/BF02772590", "article-title": "Isolation of plasmid DNA rescued from single colonies of Agrobacterium tumefaciens by means of rolling circle amplification", "volume": "21", "author": "Chen", "year": "2003", "journal-title": "Plant Mol Biol Rep"}, {"key": "10.1002/ijc.22138-BIB44|cit45", "doi-asserted-by": "crossref", "first-page": "787", "DOI": "10.1093/protein/gzh091", "article-title": "Construction of stabilized proteins by combinatorial consensus mutagenesis", "volume": "17", "author": "Amin", "year": "2004", "journal-title": "Protein Eng Des Sel"}, {"key": "10.1002/ijc.22138-BIB45|cit46", "doi-asserted-by": "crossref", "first-page": "333", "DOI": "10.1128/AAC.46.2.333-343.2002", "article-title": "SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia", "volume": "46", "author": "Li", "year": "2002", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1002/ijc.22138-BIB46|cit47", "doi-asserted-by": "crossref", "first-page": "1947", "DOI": "10.1128/JCM.40.6.1947-1957.2002", "article-title": "Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases", "volume": "40", "author": "Hujer", "year": "2002", "journal-title": "J Clin Microbiol"}, {"key": "10.1002/ijc.22138-BIB47|cit48", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1093/bioinformatics/14.1.55", "article-title": "Combinatorial pattern discovery in biological sequences: the TEIRESIAS algorithm", "volume": "14", "author": "Rigoutsos", "year": "1998", "journal-title": "Bioinformatics"}, {"key": "10.1002/ijc.22138-BIB48|cit49", "doi-asserted-by": "crossref", "first-page": "1439", "DOI": "10.1002/pmic.200300680", "article-title": "RELIC-a bioinformatics server for combinatorial peptide analysis and identification of protein-ligand interaction sites", "volume": "4", "author": "Mandava", "year": "2004", "journal-title": "Proteomics"}, {"key": "10.1002/ijc.22138-BIB49|cit50", "first-page": "757", "article-title": "Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library", "volume": "13", "author": "Shukla", "year": "2005", "journal-title": "Oncol Rep"}, {"key": "10.1002/ijc.22138-BIB50|cit51", "doi-asserted-by": "crossref", "first-page": "951", "DOI": "10.1002/ijc.20306", "article-title": "Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells", "volume": "111", "author": "Pero", "year": "2004", "journal-title": "Int J Cancer"}, {"key": "10.1002/ijc.22138-BIB51|cit52", "doi-asserted-by": "crossref", "first-page": "11918", "DOI": "10.1074/jbc.M111816200", "article-title": "Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7", "volume": "277", "author": "Pero", "year": "2002", "journal-title": "J Biol Chem"}, {"key": "10.1002/ijc.22138-BIB52|cit53", "doi-asserted-by": "crossref", "first-page": "29046", "DOI": "10.1074/jbc.272.46.29046", "article-title": "Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain", "volume": "272", "author": "Oligino", "year": "1997", "journal-title": "J Biol Chem"}, {"key": "10.1002/ijc.22138-BIB53|cit54", "doi-asserted-by": "crossref", "first-page": "17332", "DOI": "10.1073/pnas.0508809102", "article-title": "Cell-free cloning using \u03d529 DNA polymerase", "volume": "102", "author": "Hutchison", "year": "2005", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/ijc.22138-BIB54|cit55", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1002/adfm.200304501", "article-title": "Peptide-templates for nanoparticle synthesis derived from PCR-driven phage display", "volume": "14", "author": "Naik", "year": "2004", "journal-title": "Adv Func Mater"}, {"key": "10.1002/ijc.22138-BIB55|cit56", "doi-asserted-by": "crossref", "first-page": "30382", "DOI": "10.1074/jbc.M203547200", "article-title": "In situ phage screening. A method for identification of subnanogram tissue components in situ", "volume": "277", "author": "Tanaka", "year": "2002", "journal-title": "J Biol Chem"}, {"key": "10.1002/ijc.22138-BIB56|cit57", "doi-asserted-by": "crossref", "first-page": "24", "DOI": "10.1016/0167-4838(82)90287-4", "article-title": "Purification and properties of the exocellular \u03b2-lactamase of Actinomadura strain R39", "volume": "700", "author": "Duez", "year": "1982", "journal-title": "Biochim Biophys Acta"}, {"key": "10.1002/ijc.22138-BIB57|cit58", "doi-asserted-by": "crossref", "first-page": "84", "DOI": "10.1126/science.279.5347.84", "article-title": "Quantitation of transcription and clonal selection of single living cells with \u03b2-lactamase as reporter", "volume": "279", "author": "Zlokarnik", "year": "1998", "journal-title": "Science"}, {"key": "10.1002/ijc.22138-BIB58|cit59", "first-page": "3558", "article-title": "Regressions and cures of melanoma xenografts following treatment with monoclonal antibody \u03b2-lactamase conjugates in combination with anticancer prodrugs", "volume": "55", "author": "Kerr", "year": "1995", "journal-title": "Cancer Res"}, {"key": "10.1002/ijc.22138-BIB59|cit60", "doi-asserted-by": "crossref", "first-page": "1507", "DOI": "10.1021/jm970779w", "article-title": "Therapeutic effects of monoclonal antibody-\u03b2-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma", "volume": "41", "author": "Svensson", "year": "1998", "journal-title": "J Med Chem"}, {"key": "10.1002/ijc.22138-BIB60|cit61", "first-page": "2357", "article-title": "In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody \u03b2-lactamase conjugates", "volume": "55", "author": "Svensson", "year": "1995", "journal-title": "Cancer Res"}, {"key": "10.1002/ijc.22138-BIB61|cit62", "doi-asserted-by": "crossref", "first-page": "1506", "DOI": "10.1110/ps.0203102", "article-title": "TEM-1 \u03b2-lactamase as a scaffold for protein recognition and assay", "volume": "11", "author": "Legendre", "year": "2002", "journal-title": "Protein Sci"}, {"key": "10.1002/ijc.22138-BIB62|cit63", "doi-asserted-by": "crossref", "first-page": "2104", "DOI": "10.1021/bi9514166", "article-title": "Modifying the specificity and activity of the Enterobacter cloacae P99 \u03b2-lactamase by mutagenesis within an M13 phage vector", "volume": "35", "author": "Siemers", "year": "1996", "journal-title": "Biochemistry"}, {"key": "10.1002/ijc.22138-BIB63|cit64", "doi-asserted-by": "crossref", "first-page": "221", "DOI": "10.1016/S0076-6879(00)26057-6", "article-title": "Fusions to \u03b2-lactamase as a reporter for gene expression in live mammalian cells", "volume": "326", "author": "Zlokarnik", "year": "2000", "journal-title": "Methods Enzymol"}, {"key": "10.1002/ijc.22138-BIB64|cit65", "doi-asserted-by": "crossref", "first-page": "1791", "DOI": "10.1158/1535-7163.MCT-05-0189", "article-title": "A \u03b2-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy", "volume": "4", "author": "Harding", "year": "2005", "journal-title": "Mol Cancer Ther"}, {"key": "10.1002/ijc.22138-BIB65|cit66", "doi-asserted-by": "crossref", "first-page": "167", "DOI": "10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.0.CO;2-9", "article-title": "Engineered protein scaffolds for molecular recognition", "volume": "13", "author": "Skerra", "year": "2000", "journal-title": "J Mol Recognit"}, {"key": "10.1002/ijc.22138-BIB66|cit67", "doi-asserted-by": "crossref", "first-page": "1473", "DOI": "10.1038/nbt911", "article-title": "Fluorobodies combine GFP fluorescence with the binding characteristics of antibodies", "volume": "21", "author": "Zeytun", "year": "2003", "journal-title": "Nat Biotechnol"}], "container-title": ["International Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.22138", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.22138", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 24]], "date-time": "2019-04-24T08:32:57Z", "timestamp": 1556094777000}, "score": 19.169022, "issued": {"date-parts": [[2007, 2, 6]]}, "references-count": 66, "journal-issue": {"published-print": {"date-parts": [[2007, 5, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1002/ijc.22138", "relation": {"cites": []}, "ISSN": ["0020-7136"], "issn-type": [{"value": "0020-7136", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}